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ABSTRACT

Canadian population demographics are shifting to an increase in aged individuals
and an increase in the prevalence of neurodegenerative diseases. The post-mitotic nature
of most neurons highlights the need to understand the etiology and early mechanisms in
neurodegenerative diseases and design targeted therapies. Currently, the etiologies of
neurodegeneration are poorly understood but oxidative stress, mitochondrial dysfunction
and inflammation are early mechanisms in Alzheimer’s disease, Parkinson’s disease and
Amyotrophic Lateral Sclerosis. An anti-aging strategy that can be adapted for use in
neurodegeneration is hormesis, where repeated low-level exposures to stressors are
beneficial to the cell. Hormesis has demonstrated efficacy in inhibiting hepatocarcinoma
in the rat through administration of dietary phenobarbital, which decreases DNA damage,
increases DNA repair, and decreases cell proliferation. Given that phenobarbital
decreases DNA damage and increases DNA repair, phenobarbital was tested as a
hormetic agent in murine neurodegeneration. The harlequin (hq) mouse is a model of
mitochondrial dysfunction and oxidative stress with cerebellar degeneration. One-monthold wild type (WT) and hq mice were administered phenobarbital in drinking water at 0,
2 or 4 ppm provided ad libitum, until euthanized at 3, 7, or 10 months of age. Eleven
parameters of nocturnal behaviour were examined in WT and hq mice (n=9 to 14). In
situ, post-mortem cerebellar tissue sections were examined for neuron loss, cell damage,
and reactive oxygen species (ROS) (n=3). In vivo cerebellar mutations were detected
using the Big Blue cII mutation assay (n=5 or 6). The transcriptome was analyzed to
survey global markers in hq cerebella and response to phenobarbital exposure (n=3). The
hq phenotype had no behavioural changes, but had increased neuron loss, limited cell
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damage, a mutation signature of ROS, and elevated ROS with age. Phenobarbital
administration did not prevent cerebellar degeneration in hq mice. Transcriptome data
revealed inflammation as an early disease mechanism in hq mice. In hq mice, a downregulation in the GABAA receptor was found which potentially limits the efficacy of
phenobarbital. The hq mouse could benefit from a strategy addressing mitochondrial
dysfunction through supplementation with riboflavin, thus increasing activity of complex
I of the electron transport chain and increasing ATP production.

Key words: harlequin mouse, cerebellar degeneration, Apoptosis-inducing factor,
phenobarbital, hormesis, inflammation, mitochondrial dysfunction, aging, murine
behaviour, Big Blue cII mutation detection assay, oxidative stress, microarray.
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1
CHAPTER ONE - INTRODUCTION

1.1 Aging-associated neurodegenerative diseases
Neurodegenerative diseases are associated with substantial economic impact on
society. In 1998, the cost of neurodegenerative diseases totaled over $400 million
dollars, which included hospital stays, treatments, and money lost from long-term
disability and premature death [1]. As of the last Canadian census, individuals aged 65
and over made up a record 13.7% of the total population [2]. Last year, 2011, was
momentous as it marked the year the first cohort of the baby-boomer generation reached
the age of 65. The proportion of individuals over the age of 65 is expected to continue
increasing until 2056, at which point seniors will constitute 25% to 30% of the total
population, more than double the current proportion [2]. As the proportion of Canadians
over the age of 65 increases, so will the frequency of neurodegenerative disease, as it is
highly correlated with age [3]. Current estimates are that over 800,000 Canadians suffer
from either Alzheimer’s disease (AD), Parkinson’s disease (PD), or Amyotrophic Lateral
Sclerosis (ALS) [2]. Biomarkers for neurodegeneration include testing cerebral spinal
fluid for amyloid

and/or tau in AD [4], or tumor necrosis factor- (TNF- ), and 8-

hydroxy-2’-deoxyguanosine (8-OHdG) in PD [5], and glutamate in ALS [6], but lumbar
punctures required to obtain cerebral spinal fluid are painful and invasive procedures.
Positron emission tomography imaging can be used to visualize the location of
neurofibrillary tangles and amyloid plaques in AD [7], the decrease of dopamine
transporters with disease progression in PD [8], or to measure glucose hypermetabolism
in ALS [9], all which require the injection of radioactive tracers. Even with the
development of early biomarkers, by the time symptoms appear, a significant number of
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neurons have already been lost [10, 11]. Currently we are unable to prevent
neurodegenerative diseases and the treatments that are available are limited to alleviating
symptoms and are not able to slow disease progression or cure neurodegeneration. A
limiting step in drug development is determining the etiology and mechanisms of
neurodegeneration.

1.2 Genetic basis behind early-onset neurodegenerative diseases
Families with early-onset neurodegenerative disorders due to single-gene
mutations have been identified and display simple Mendelian inheritance patterns [1214]. Single-gene mutations in Amyloid precursor protein, Presenilin-1, Presenilin-2, Synuclein, Parkin, and Copper/zinc superoxide dismutase genes have been identified in
familial AD [14-17], PD [12, 18], or ALS [13]. Single-gene mutations cause 5 % of the
cases of neurodegeneration [19-21], although most individuals who develop late-onset
neurodegeneration have no family history of neurodegenerative disorders. Thus earlyonset neurodegenerative disorders are a limited model when studying late-onset
neurodegenerative diseases.

1.3 Late-onset neurodegenerative disorders
The etiology of late-onset neurodegeneration is poorly understood, has no clear
genetic basis and combines complex interactions between genes and the environment.
Several susceptibility genes have been identified in sporadic cases of neurodegeneration,
but brain injuries and environmental exposure to pesticides as well as heavy metals all
increase the risk of developing neurodegeneration. Individuals who experience a
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traumatic brain injury have an increased risk of AD [22] that is further exacerbated when
they also have the epsilon 4 allele of the Apolipoprotein E gene [23]. Individuals
chronically exposed to pesticides have a 70% higher incidence of PD compared to
individuals not chronically exposed to pesticides [24]. It is thought that the link between
pesticides and PD lies in the activity of the enzymes that are involved with the
detoxification, metabolism, and transport of xenobiotics. The cytochrome P450 enzyme
2D6 (CYP2D6) is involved in the metabolism of pesticides. Individuals with a
polymorphism in the CYP2D6 enzyme causing lower CYP2D6 activity and poor
pesticide metabolism have a higher incidence of PD [25, 26]. In ALS patients, elevated
iron levels are detected [27] that can be due to alterations in a number of genes involved
in iron transport [28]. Iron enters neurons though a complex composed of transferrin and
its receptor [29, 30] and the gene Ferroportin-1 is responsible for neuronal iron export
[31]. Dysregulation of genes involved in iron transport could lead to increased
intracellular levels of iron, causing oxidative stress, inflammation, and microglial
activation [28]. This highlights the importance of gene and environmental interactions
and the complexity of disease triggers and genetic basis of disease mechanisms.

1.4 Early mechanisms underlying aging-associated neurodegeneration
1.4.1 Oxidative stress as a common denominator in aging-associated neurodegeneration
One suggested theory of neurodegeneration is that aged neurons have increased
levels of oxidative stress with negative impact on lipids, proteins, RNA, and DNA.
Oxidative stress is caused by reactive oxygen species (ROS), metabolites of molecular
oxygen that include lipid peroxide, hydrogen peroxide, and the superoxide anion [32].
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The free radical theory of aging suggests that ROS are generated as a byproduct of
metabolism and cause damage to cellular components that accumulate over time,
resulting in aging and death [33]. The brain is particularly susceptible to oxidative stress
because of its high levels of oxygen consumption [34], metabolic activity [35], and
concentration of polyunsaturated fatty acids (PUFA) [36, 37]. Oxidative stress-induced
damage to proteins, lipid membranes, and nucleic acids are observed in
neurodegenerative diseases [38-40]. Protein oxidation leads to structural alterations and
subsequent loss of enzymatic activity critical for neuronal function [41]. Membrane
integrity is disrupted given the vulnerability of PUFAs to free radical attack since double
bonds allow easy removal of hydrogen atoms by ROS [42]. Unrepaired DNA damage
can result in an accumulation of DNA adducts in both nuclear and mitochondrial
genomes and can inhibit binding of transcriptional and regulatory factors. Lipofuscin is a
fluorescent pigment composed of approximately 60-70% proteins, 16-27% oxidized
lipids, and 1.0 – 1.7% metals [43] that accumulates with age in lysosomes of post-mitotic
cells such as cardiac myocytes [44], retinal cells [45], and other neurons [44, 46]. The
presence of lipofuscin is detected with age in neurons in numerous organisms including
rodents [46], monkeys [47], and humans [48]. Lipofuscin cannot be degraded by
lysosomal enzymes due to the presence of peptides cross-linked by aldehydes into
plastic-like structures [49] that is of particular importance since lipofuscin can negatively
impact cellular processes including protein degradation [45]. Collectively, oxidative
damage can lead to abnormal functioning of neurons and apoptosis or necrosis.
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1.4.2 Mitochondrial dysfunction in aging-associated neurodegeneration
The mitochondria are responsible for producing energy in the form of adenosine
triphosphate (ATP) during oxidative phosphorylation but they are also the major source
of ROS. NADH is oxidized by complex I of the electron transport chain and the
electrons are transferred to coenzyme Q while pumping protons across the mitochondrial
membrane, creating a proton gradient [50]. Approximately 4-5% of the time, oxygen is
capable of stealing electrons from the electron transport chain components to generate the
superoxide radical [51]. The main sources of the superoxide radical are complexes I and
III of the electron transport chain [52, 53]. Mitochondria are particularly vulnerable to
ROS damage as the mitochondrial DNA is in close proximity to ROS production and
does not contain histones or other DNA-associated proteins and thus is exposed directly
to attack by ROS. Mitochondrial DNA lacks introns [54] and has a low repair rate [55],
resulting in a high probability of ROS damaging or modifying a coding region. As a
result of damage to mitochondrial components, there is a decrease in the amount of
energy production and an increase in ROS production which can lead to apoptosis [56].
Both decreased energy production and mitochondrial dysfunction have been detected in
AD [57, 58], PD [59, 60], and ALS [61].

1.4.3 Inflammation in aging-associated neurodegeneration
Inflammation, which is due to the activation of the immune response, is generally
protective in that it is an attempt by the organism to remove invading microorganisms as
well as damaged and dying cells to initiate the healing process. Inflammation in the
central nervous system occurs through the activation of microglia. Microglia are the
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resident macrophages of the central nervous system [62], capable of scavenging infected
[63], damaged [64], or apoptotic neurons [65]. Once microglia become activated, they
express surface receptors including the major histocompatibility complex [66] and
complement receptors [67]. These cells also undergo changes in morphology from a
ramified shape to a mobile amoeboid shape [68]. Activated microglia can secrete
complement proteins [69], cytokines [70, 71], chemokines [72], ROS [73], proteases [74,
75], excitatory amino acids [76], and nitric oxide [77]. If the agent causing inflammation
is not removed, then this can then lead to constant microglial activation and a chronic
inflammatory state. Activated microglia can be found in close proximity to amyloid
deposits in AD [78] and amyloid

is known to stimulate the release of interleukin-1 (IL-

1) [72], interleukin-6 (IL-6) [79], tumour necrosis factor- (TNF- ) [72, 80],
macrophage inflammatory protein-1

(MIP-1 ) [72], monocyte chemoattractant protein-

1 (MCP-1) [79], nitric oxide [77], and superoxide radicals [81] from activated microglia.
Activated microglia are detected in the substantia nigra of PD patients [82]. Similar to
AD, activated microglia in PD release TNF- [83], IL-1 , interferon- (IFN- ) [84],
inducible nitric oxide synthase (iNOS) [83], and cyclooxygenase-2 (COX-2) [85]. The
release of inflammatory cytokines as well as factors released from dying neurons can
amplify the inflammation and lead to further neuronal injury and death. Microglial
activation is found in the prefrontal cortex, motor cortex, thalamus, and the pons in
patients with ALS [86]. Targeting the inflammatory response may be of therapeutic
benefit since nonsteroidal anti-inflammatory drugs decrease the risk of AD [3], inhibition
of iNOS provides neuroprotection in PD [87], and minocycline improves motor
performance and survival in a mouse model of ALS [88].
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1.4.4 Gene expression in aging-associated neurodegeneration
The neurodegenerative disease process is complex and involves the interaction of
many different pathways and genes. Changes in the gene expression profile with
neurodegenerative diseases can provide information about the onset and progression of
the diseased state and lead to understanding of the disease pathology. In AD, an upregulated immune response involving complement genes is detected in the entorhinal
cortex, hippocampus, and midtemporal gyrus in the brain [89]. Elevated expression of
chemokines and cytokines in AD [90] are capable of inducing iNOS activity [91].
Cytokines are also able to activate microglia [92] and astrocytes [93], further propagating
inflammation. There is reduced expression of genes involved in energy metabolism
leading to decreased mitochondrial function and ATP production in AD [94]. Also, there
is a down-regulation in genes that code for cytoskeleton proteins [95] that can lead to
dysfunction in cellular transport [96].
Gene expression changes in PD include up-regulated genes involved in the
immune and inflammatory response [97], indicating a role in the activation of glial cells
in PD pathology. In PD, there is an up-regulation of genes involved in apoptosis leading
to increased cell death [98]. Genes involved in cytoskeleton maintenance are downregulated [98] that can affect cellular trafficking, cell-to-cell contact, and stability.
Mitochondrial genes involved in proper function and energy synthesis are downregulated [97, 98] that could lead to impaired energy production. There is a downregulation in an antioxidant enzyme [98], leading to decreased protection in the cell from
ROS [99]. Genes involved in proteolytic machinery to degrade misfolded and damaged
proteins are down-regulated [97, 98] that can lead to accumulation of aggregated proteins
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and inhibition of proteasomal function [100]. Genes involved in synaptic function ( aminobutyric acid (GABA) transporter and receptors), are down-regulated [98] that
disrupts signal transmission and communication between neurons. Ion channels are also
down-regulated [97, 98], leading to altered maintenance of the electrochemical gradients.
Dysregulation of ion channels has been implicated in PD pathogenesis [101].
Gene expression changes in ALS diseased brains include an up-regulation of
glutamate receptors [102, 103] that can lead to excitotoxicity [104]. There is downregulation of genes involved in zinc and iron homeostasis [102], suggesting a role of
metal imbalance in ALS [105]. Down-regulation in proteasomal function is also detected
in ALS [102, 103] and can lead to an increase in misfolded proteins [106]. Genes
involved in the organization of the cytoskeleton are also down-regulated [102, 103] and
can lead to disruption in axonal transport [107]. There is also a down-regulation of genes
that inhibit apoptosis [102], thus promoting apoptosis [108, 109]. Genes involved in
mitochondrial metabolism and energy production are down-regulated [102, 103] and can
lead to impaired energy production. Genes associated with neuroprotection, such as heat
shock proteins and antioxidants are down-regulated [102, 110], indicating a lack of
ability to deal with increased oxidative stress and inflammation. Up-regulation of genes
involved in inflammation cascades including the Interleukin-1 receptor accessory protein
(IL-1RAP), the Chemokine (C-C motif) ligand 5 (CCL5), and Glial fibrilary acidic
protein (GFAP) have been identified [111]. IL-1RAP is a transmembrane receptor
complex that binds to IL-1 [112], which can lead to the downstream transduction of
inflammatory effects of IL-1 [113]. The cytokine CCL5 is a proinflammatory
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chemoattractant for glial cells [114] and GFAP, a marker of astrogliosis [115], indicates
that glial cell activation is a pathological event in ALS.

1.5 The use of mice in studying neurodegeneration
Studying neurodegeneration in humans is difficult to do, as scientists cannot control
for diet, environment, or the genetics of human subjects, not to mention that acquiring
access to neurodegenerative human brain tissue could be a lengthy process due to limited
supplies from the declining rate of autopsies [116]. Also, precautions need to be taken
when handling human tissue, as it may contain infectious agents such as the hepatitis
virus, human immunodeficiency virus, and prions, all of which can be transmitted to
other humans [117]. Model organisms of neurodegeneration are valuable tools allowing
the study of the pathological mechanisms as well as new treatments in complex diseases.
Drosophila melanogaster, Caenorhabditis elegans and Danio rerio have been used to
study neurodegenerative disease mechanisms [118-120], but their simpler nervous
systems limit the translation to human-specific neurodegenerative diseases. Mice are
commonly used in neurodegenerative research as a mammalian model of human disease
due to similar genetic composition to humans with 99% of human genes having a mouse
homolog [121]. Mice also have similar physiology to humans [122], are small in size,
easy to handle and house, and have large litter sizes and short generation times. Despite
the obvious difference in size, all the major brain structures that are present in humans are
also present in rodents. However, one major difference is that in humans, the cortex
contains a large area devoted to vision, while in rodents the visual area is smaller since
they rely more on auditory and olfactory cues. Despite these differences, gene expression
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in the brain is similar between the two species [123]. Thus mice can be useful tools in
studying neurodegeneration.

1.6 Mice having aging-associated neurodegeneration
Mice show limited neuron loss with aging [124-126], but transgenic animal models
have been created in order to mimic human neurodegenerative diseases. Although no
transgenic model is able to replicate exactly all features of a particular neurodegenerative
disease, mouse models can nonetheless display the different disease pathologies. The
triple transgenic mouse (3xTg) for AD, (3xTg-AD), is the only AD mouse that displays
both amyloid

plaques and neurofibrillary tangles [127]. At 6 months of age, the 3xTg-

AD mouse has a 14.8 fold up-regulation of the pro-inflammatory cytokine, TNF- , and a
10.8 fold up-regulation of the pro-inflammatory chemokine, MCP-1, as well as activated
microglia in the entorhinal cortex [128]. The 3xTg-AD mouse also shows elevated
oxidative stress, a 20% reduction in hippocampal mitochondrial DNA, and decreased
complex IV and V of the electron transport chain [129]. Another 3xTg-AD mouse model
shows decreased activity of complex I and IV in the mitochondrial electron transport
chain, decreased membrane potential, and increased ROS [130].
A PD mouse model that overexpresses -synuclein leads to microglial activation,
increased TNF- , IL-1 , COX2, NOX2, iNOS, and increased ROS production [131].
Synuclein localizes to complex I in neuronal cells [132] and it has been documented in
vitro and in vivo that overexpression of -synuclein inhibits complex I and increases
ROS production [133, 134].
A mouse model of ALS that contains a mutated Superoxide dismutase-1 (mSOD1)

-
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gene with a glycine to alanine substitution at codon 93 (G93A), has swollen
mitochondria, decreases in activity of complex IV of the electron transport chain, and
elevated levels of ROS [99]. In cell cultures, extracellular mSOD1-G93A is capable of
activating microglia [135] but activated microglia containing the mSOD1-G93A are more
neurotoxic than activated wild type (WT) microglia [136], likely through the elevated
production of superoxide anions, nitric oxide, and peroxynitrite radicals [99]. In fact,
replacement of microglia in mSOD1-G93A transgenic mice with microglia expressing
WT SOD1 slows disease progression and increases survival [137], indicating microglial
activation as a source of neuroinflammation in mSOD1-G93A mice.

1.7 Altered mouse behaviour with neurodegeneration
In humans, neurodegenerative diseases are characterized by cognitive decline and
motor deficits including slower gait and decreased stride length that can be detected in
individuals prior to confirmation with post-mortem analysis [138-141]. Behavioural
differences can also be detected in mouse models of neurodegeneration. The 3xTg-AD
mouse has similar locomotor activity as non-transgenic WT controls prior to disease
onset and has decreased activity at 15 months of age, but with no impairment in balance
[142]. A different mouse model of AD, expressing human P301S tau protein,
demonstrates elevated locomotor activity but decreased motor co-ordination compared to
non-transgenic WT controls [143]. Mouse models of PD caused by administration of the
neurotoxin 1-methyl 4-phenyl 1-,2-, 3-, 6-tetrahydropyridine (MPTP), depleting the brain
of dopamine, display motor deficits [144, 145]. The major changes include a decrease in
stride length and duration that leads to an increase in frequency of steps, indicating that
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MPTP-treated mice are taking more steps in a shorter period of time when compared to
controls [145]. A different mouse model of PD, which overexpresses a mutated version
of the human -Synuclein gene, displays decreased locomotion, with impaired motor coordination and balance [146]. The ALS mouse model containing a G93A substitution in
the SOD1 gene shows gait disturbances with an increase of time spent in the propulsion
portion of the stride, an increase in stride time, a decrease in stride frequency, and a
decrease in walking velocity [147]. Thus, mouse models of neurodegeneration exhibit
phenotypes consistent with affected humans suggesting that they are useful tools in the
study of neurodegenerative diseases through the monitoring of early biological markers
of altered animal behaviour. Early markers widen the window of opportunity for
treatment to delay or prevent the occurrence of severe disease symptoms.

1.8 Human cerebellar ataxias are a model of neurodegeneration
Human cerebellar ataxias have a strong behavioural component and the genetics
behind the most common cerebellar ataxias in humans are well known. The most
common autosomal recessive cerebellar ataxia is Friedreich’s ataxia due to a GAA triplet
repeat expansion in the Frataxin gene [148]. Ataxia telangiectasia is the second most
common autosomal recessive cerebellar ataxia due to a mutation in the Ataxia
telangiectasia mutated gene [149]. There are also autosomal dominant cerebellar ataxias
that are caused by the trinucleotide CAG repeat expansion leading to spinocerebellar
ataxia [150]. Cerebellar ataxias have early onset of disease [151, 152] and known genetic
etiologies making these diseases very specific examples of neurodegeneration. To
understand general mechanisms of aging-associated neurodegenerative disorders, genetic
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models of cerebellar degeneration with predominant neurodegenerative phenotypes are
needed.

1.9 The cerebellum as a model for studying neurodegenerative diseases
The brain is a complex tissue to study as it consists of different anatomically and
histologically distinct areas with different neuronal and non-neuronal cell types [153].
Also, neurodegeneration tends to occur in distinct regions of the brain such as the
cerebral cortex and hippocampus in AD, substantia nigra in PD, and in upper and lower
motor neurons in the motor cortex, brain stem, and spinal cord in ALS. Thus, in order to
study pathological changes in the brain, it would be better to focus on a specific area with
a certain cell type rather than a whole brain region.
The cerebellum is an ideal brain area of study since the majority of neurons are
located in the cerebellum [154]. Also, the cerebellum shows degenerative changes in
humans with neurodegenerative disorders such as AD, PD, and ALS. Atrophy of the
neuronal layers, decreased neuronal density, decreased synapses, and amyloid
accumulations are observed in the cerebella of patients with AD [155-159]. Atrophy of
the posterior cerebellum is also associated with poorer cognitive performance in
individuals with AD [160]. In PD, there is a reduction in the amount of cerebellar
inhibition leading to the generation of postural tremor [161]. Changes in the cerebella
have been reported in ALS, including loss of Purkinje cells and basophilic inclusions,
which are a pathologic feature in ALS [162]. Also, uncoordinated movement is a
common feature in neurodegenerative diseases [163-165] and the cerebellum plays a role
in motor control [166].
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1.10 The function and organization of the cerebellum
The cerebellum is involved in motor control but specifically co-ordination and
fine-tuning of movements. Electrical stimulation of the cerebellum does not cause
sensation or produce motor movements, yet the cerebellum is vital for movements that
require co-ordination of different muscle groups like running and playing the piano. The
role of the cerebellum in movement was first discovered after World War I, where
individuals with lesions in the cerebellum lost the ability to move properly [167]. Their
movements were ataxic and they had problems with muscle weakness, posture, and
balance without signs of paralysis [167, 168]. The cerebellum receives sensory
information from voluntary muscle movements, compares those movements with what
was intended by the motor cortex, and is able to make corrective adjustments during
execution [169-171].
In order to understand the function of the cerebellum, knowledge of the structure
and organization of the cerebellar circuitry is needed. The cerebellum is located at the
base of the brainstem and can be divided medio-laterally and anterior-posteriorly (Figure
1.1a). Medio-laterally the cerebellum can be divided into the vermis and two lateral
hemispheres [172]. In the anterior-posterior direction, two fissures divide the vermis
cerebellum into three major lobes. The primary fissure separates the anterior and
posterior lobes, and the posterolateral fissure separates the flocculonodular lobe from the
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Figure 1.1 - A dorsal view of the mouse brain

Figure 1.1 – A dorsal view of the mouse brain. A) The location of the cerebellum in
relation to other structures of the mouse brain. The cerebellum is divided medio-laterally
into the vermis and the hemispheres. The image of the whole mouse brain was taken by
Eric Diehl. B) A schematic diagram of the unrolled cerebellum from anterior to posterior.
The fissures separate the cerebellum into different lobes.
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posterior lobe [172] (Figure 1.1b). Due to the fact that the cerebellum contains the
majority of neurons in the brain in such a small space [173-175], the cerebellum is
intricately folded and the lobes can be further divided into ten lobules numbered with
Roman numerals I–X [172] (Figure 1.2a). Gene expression patterns however, suggest
that there are four different zones including the anterior zone (AZ: lobules, I-V), the
central zone (CZ: lobules VI, VII), the posterior zone (PZ: lobules VIII, IX), and the
nodular zone (NZ: lobule X) [176].
The cerebellum consists of four distinct layers (Figure 1.2b). The molecular layer
contains scattered stellate and basket neurons that are inhibitory in nature. The next layer
is the single cell layer of Purkinje cells. Underneath the Purkinje cell layer is the granule
layer, which consists of densely packed granule cells and scattered Golgi cells with a
granule cell to Golgi cell ratio of 414:1 [177]. And lastly, the white matter layer contains
myelinated afferent (input) and efferent (output) fibers as well as the deep cerebellar
nuclei. The afferents to the cerebellum are climbing fibers and mossy fibers (Figure 1.3).
The climbing fibers originate from the inferior olive in the medulla oblongata in the
brainstem and synapse on the deep cerebellar nuclei as well as on Purkinje cells in the
cerebellar cortex. Mossy fibers on the other hand originate from various regions
including the spinal cord and the precerebellar nuclei in the hindbrain [178], and synapse
on the deep cerebellar nuclei [179] and granule cells [180]. Both climbing and mossy
fibers are excitatory. Climbing fibers release aspartate [181] and glutamate [182], and
mossy fibers release glutamate [183] and acetylcholine [184, 185]. The axons of granule
cells, also called parallel fibers, synapse onto the dendrites of Purkinje, basket, stellate,
and Golgi cells and are able to induce excitation.
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Figure 1.2 - The structure and organization of the mouse cerebellum

Figure 1.2 – The structure and organization of the mouse cerebellum. A) An image
of a sagittally sectioned mouse cerebellum stained with hematoxylin and eosin showing
the organization of the lobules labeled with Roman numerals I-X [172]. B) Histology of
the four different layers in the mouse cerebellum. The cryopreserved cerebellum was
sagittally sectioned to a thickness of 10 µm and stained with hematoxylin and eosin.
Arrows are pointing to the different layers of the cerebellum. The molecular layer
contains stellate and basket neurons. The Purkinje cell layer is a single cell layer
comprised of Purkinje cells. The granule layer contains granule cells and Golgi cells.
The layer of white matter contains both afferent (input) and efferent (output) fibers of the
cerebellum. Scale bars: A = 1 mm, B = 100 µm
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Figure 1.3 - A schematic diagram of the circuitry of the cerebellum

Figure 1.3 - A schematic diagram of the circuitry of the cerebellum. Input into the
cerebellum in the form of mossy and climbing fibers originates in the precerebellar nuclei
and the inferior olive respectively. Mossy fibers synapse onto granule cells and the deep
cerebellar nuclei and climbing fibers synapse onto Purkinje cells and the deep cerebellar
nuclei. Purkinje cells are the point of convergence of multiple signals from climbing
fibers, granule cells, basket cells, and stellate cells. Purkinje cell output can be inhibited
by basket and stellate cells and excited by granule cells. Purkinje cells then send
inhibitory signals to the deep cerebellar nuclei in the white matter. Golgi cells can inhibit
granule cell output. Mossy fibers, climbing fibers, and granule cells induce excitation, all
other neurons in the cerebellum induce inhibition.
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Basket cells and stellate cells inhibit Purkinje cells, and Golgi cells inhibit the mossy
fiber-granule cell synapse [180]. Purkinje cells are the point of convergence of separate
incoming signals and are the sole efferents of the cerebellar cortex, which is inhibitory in
nature. The axons of Purkinje cells synapse onto the deep cerebellar nuclei in the white
matter of the cerebellum [186], as well as the vestibular nuclei located in the medulla
[187]. The efferent fibers of the deep cerebellar nuclei send excitatory signals to the
thalamus and various regions in the brainstem including red nucleus, the vestibular
nuclei, and the inferior olive [188, 189] (Figure 1.4). The thalamus receives input from
the cerebellum and the basal ganglia, and projects the input to the motor cortex [190,
191]. The brainstem sends output to muscles [192] and the motor cortex [193, 194] and
the motor cortex relays the information to the brainstem. Mossy and climbing fibers of
the precerebellar nuclei and inferior olive synapse on granule cells and Purkinje cells
respectively, but also on deep cerebellar nuclei in the cerebellum, thus forming the
cerebrocerebellar communication loop.
1.11 Age-associated changes in the cerebellum
The human cerebellum shows a number of age-associated changes including the
reduction of cerebellar mass, loss of white matter volume, reduction of the volume of the
perikaryon, and loss of Purkinje and granule cells [195]. A previous study determined
that there is a 27% reduction of myelinated fibers with age in the cerebrum [196], which
could potentially be the origin of the decrease in white matter in the cerebellum. Gene
expression analysis of the aging cerebellum in mice shows alterations in lipid
biosynthesis [197], possibly leading to defective myelin synthesis and signal
transduction. Aged mice also have a reduced number of Purkinje cells [124, 198, 199],
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Figure 1.4 - A schematic diagram of the involvement of the cerebellum in
coordinated movement

Figure 1.4 – A schematic diagram of the involvement of the cerebellum in cocoordinated movement. To initiate movement, the motor cortex sends signals to the
muscles and the cerebellum. The cerebellum receives input from the motor cortex and
the muscles, compares the two signals and modifies the signal back to the motor cortex
and muscles via the thalamus, brainstem, and spinal cord.
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basket cells, and stellate cells [124]. Decreased Purkinje cell numbers are detected at 18
months of age in C57Bl/6J [198] and CBA [199] inbred mouse strains. In addition, genes
involved in cellular immune and inflammatory responses are up-regulated in the
cerebellum with age in seven different inbred mouse strains (129sv, BALB/c, CBA,
DBA, C57BL, C3H and B6C3F1) [200]. Other studies have shown increases in genes
associated with apoptosis and mitochondrial dysfunction and decreases in neurotrophic
factors [201, 202]. All of these responses have been implicated in normal human brain
aging [203].

1.12 Similarities and differences in the human and mouse cerebellum
The most obvious difference between the human and mouse cerebellum is size.
The average surface area of the human cerebellum is 1,128 cm2 compared to the mouse
cerebellum at 190 mm2 [204]. The larger surface area in the human cerebellum increases
the complexity of the convolutions in the cerebellum, but the major cerebellar lobules can
be identified in humans and mice. Due to evolution from a common ancestor, the
cerebellum is present in all vertebrate brains [205]. Despite the similar structures and
organization of the cerebellum, the functional topography of the cerebellum, on the other
hand, is complex and assumptions cannot be made regarding the functionality of the same
lobule in different species as determined through electrophysiological mapping [206].
Humans have four deep cerebellar nuclei (dentate, emboliform, globose, fastigial), and
mice have three (dentate, interpositus, fastigial), but the neurons in the cerebellum and
their connections are the same in humans and mice. Overall, the similarities in the
cerebellar structure, organization, function, and aging in the human and mouse
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cerebellum make mouse models an acceptable choice for the examination of cerebellar
disease mechanisms.

1.13 Mouse models of cerebellar degeneration
Several mouse models of cerebellar degeneration have been characterized.
Leaner mice are the result of a recessive mutation for a component of the voltage-gated
calcium channel, mimicking spinocerebellar ataxia type 6 [207]. Granule cell death is
detected at postnatal day 10 with the most dramatic loss occurring between postnatal day
15 and 40 in leaner mice [208]. Purkinje cell loss is minor until postnatal day 26 then
degeneration accelerates for the next 4 to 6 weeks in leaner mice [208]. The
heterozygous lurcher mouse contains a mutation in the Glutamate receptor delta-2
subunit gene [209], causing large scale degeneration of the cerebellar Purkinje and
granule cells starting at postnatal day 8 [210], with almost no Purkinje cells and few
granule cells remaining at postnatal day 90 [211]. The staggerer mutant mouse has a
deletion of the Rora gene which codes for a retinoid-like nuclear receptor involved in
neuronal differentiation and maturation and is expressed in high levels in the cerebellar
Purkinje cells [212]. In staggerer mice, Purkinje cells are reduced in number prior to
postnatal day 5 and only 25% of Purkinje cells are left at the end of the first postnatal
month [213]. Granule cells are nearly all degenerated by the end of the first postnatal
month [214], but this is secondary to the Purkinje cell degeneration [215]. Reeler mice
have a mutation in the Reln gene, which encodes the protein REELIN, an extracellular
matrix protein involved in neural adhesion and migration during development [216]. The
mutation in Reln leads to disorganization of cells in the cerebellum [217], inferior olive
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[218], cochlear nucleus [219], dopaminergic neurons [220], and hippocampus [221].
Approximately 50% of Purkinje cells degenerate in reeler mice [222]. The weaver
mouse contains a mutation in the G-protein-gated potassium channel 2 (Grik2) gene that
codes for a rectifying potassium channel [223] resulting in loss of almost all granule cells
[224] and 28% of Purkinje cells are lost by 3 months of age [225]. The loss of granule
cells occurs just shortly after birth, prior to migration into the internal granule cell layer
[224]. In addition, these mouse models of cerebellar degeneration leaner, lurcher, reeler,
staggerer, and weaver display ataxia or disturbances in gait [226-231]. However, it is
important to note that these mouse models of cerebellar degeneration all display loss of
Purkinje and granule cells with early disease onset in the postnatal period, which does not
make them ideal mouse models in testing anti-aging strategies. An ideal mouse model
would be symptom-free at young ages, and have a late onset of cerebellar degeneration
that allows for a wide treatment window.

1.14 The harlequin mouse as a model of oxidative stress and cerebellar
neurodegeneration
The harlequin (hq, XhqY) mouse is a model of mitochondrial dysfunction leading
to elevated oxidative stress and retinal and cerebellar neurodegeneration [232-234]. The
hq mouse contains a proviral insertion in the first intron of the X-linked Apoptosisinducing factor (Aif) gene, also known as Programmed cell death 8 (Pdcd8) [232]. The
proviral insertion results in aberrant splicing and a reduction in Aif expression in all
tissues examined including the cerebrum, cerebellum, retina, heart, kidney, muscle, lung,
spinal cord, stomach and liver [232, 233, 235]. Under normal conditions, AIF is located
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in the inner [236] and outer [237] mitochondrial membrane, but AIF induces apoptosis
when translocated to the nucleus inducing chromatin condensation and large scale DNA
fragmentation [238].
Despite the fact that hq mice arose due to a single gene mutation, the phenotype
of the hq mouse is quite complex and can be used to model changes in behaviour,
oxidative stress, and mitochondrial dysfunction. Aif has sequence similarity to bacterial
oxidoreductases [238] and thus may be able to convert hydrogen peroxide to water, with
AIF deficiency leading to an increase in ROS production and oxidative stress [232].
Neurons and cardiomyocytes from hq mice are sensitive to hydrogen peroxide induced
cell death [232, 235], and heart tissue when examined for increased oxidative stress has
elevated levels of the superoxide radical [239]. Elevated levels of superoxide radicals are
also detected in the skin of hq mice, which are also accompanied by a 1.7-fold increase in
mutation frequency [240]. Using the human placental alkaline phosphatase (PLAP)
assay, capable of detecting a single guanine deletion, the mutant frequency in the brain of
hq mice is 3-fold higher when compared to WT mice [241]. This elevation in brain
mutant frequency does not change with age and is not seen in the kidney, heart, and liver
in hq mice [241]. This elevated mutant and mutation frequency in hq mice contrasts to
previous studies where spontaneous mutation frequency in C57Bl/6J mice is similar
regardless of tissue type from 3 to 10 months of age [242, 243]. Increases in mutation
frequency from 10 to 25 months of age are reported in liver and adipose tissue, while the
mutation frequencies in brain and male germ-line remain low throughout development
and into old age in C57Bl/6J mice [242-244]. In hq mice, the olfactory epithelium has
increased lipofuscin autofluorescence and increased oxidative damage to RNA and
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mitochondrial DNA as well as increased apoptotic cells [245]. The sensitivity displayed
by neurons, cardiomyocytes, skin, and olfactory epithelium to oxidative stress and
increased markers of oxidative stress in tissues from hq mice and AIF-knockout mice
suggests a role of AIF as an antioxidant enzyme [232, 239-241, 246, 247].
AIF plays an undefined role in oxidative phosphorylation (OXPHOS), perhaps
related to correct assembly and/or maintenance of the respiratory chain complex I [248].
Decreased activity of complex I and III of the electron transport chain are detected in the
brain and retinal tissue but not in the muscle or kidney from hq mice [248]. AIFknockout embryonic stem cells or AIF knockdown cell lines are associated with
decreased complex I proteins [248-250]. A targeted deletion of the Aif gene in striated
muscle leads to increased mitochondrial dysfunction, dilated cardiomyopathy, atrophy of
skeletal muscle, and death at 4 months of age [246]. Complete Aif-knockout is lethal in
mouse embryos with death occurring at embryonic day 11 [251]. Human patients with
mitochondrial disorders also have similar defects in oxidative phosphorylation in a tissuespecific manner [252, 253]. Two related individuals, with a trinucleotide deletion in exon
5 of the Aif gene, were identified recently [254]. Both individuals presented with
developmental delay, hypotonia, an absence of reflexes, muscle atrophy, and reduced
activity of the electron transport chain complexes III and IV [254]. Altogether these
results suggest a role of AIF in mitochondrial electron transport chain assembly or
maintenance.
In the olfactory epithelial tissue, global analysis of gene expression in hq mice has
only been examined at 6 months of age. Altered genes were classified into categories of
cell signaling/apoptosis, oxidative stress/aging, cytoskeleton/extracellular matrix
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transport, and neurogenesis [245]. The Programmed cell death 6 (Pdcd6) gene is upregulated in hq mice, and is induced by endoplasmic reticulum stress, and mediates a cell
death pathway [255]. Pdcd6 also accelerates apoptosis mediated by caspase-3 [256].
Another gene induced by endoplasmic reticulum stress, Dnaj homolog, subfamily C,
member 10 (Dnajc10), is up-regulated in hq mice. Dnajc10 is required for the correct
folding of proteins in the endoplasmic reticulum [257]. Up-regulated genes involved in
the endoplasmic reticulum stress response could be due to misfolded proteins that can be
induced by oxidative stress [258]. Genes involved in DNA repair, are also up-regulated
in the olfactory epithelial tissue in hq mice [245]. The expression of the Damage-specific
DNA binding protein-1 gene, a component of nucleotide excision repair [259], and the
Werner syndrome gene, a DNA repair gene [260], are elevated consistent with oxidative
DNA damage. The Chemokine (C-X-C motif) ligand-12 (Cxcl12) gene is up-regulated in
the olfactory epithelium and attracts immune cells to a site of injury or infection [261]
and could lead to immune system activation and inflammation. In fact, a previous study
shows an increase in macrophage recruitment in the olfactory epithelium following largescale apoptosis [262]. Down-regulated genes in the olfactory epithelium in hq mice are
involved in cytoskeleton organization, which includes Protein tyrosine kinase-2 [245].
Protein tyrosine kinase-2 is involved in the disassembly of focal adhesions [263] and
may lead to increased cell migration or limit the proliferation of progenitor cells. The
Cyclin D2 gene is down-regulated in the olfactory epithelium in hq mice and is required
for adult neurogenesis [264] that occurs in the olfactory epithelium [265, 266]. The Bone
morphogenetic protein receptor type-1 A gene is also down-regulated and promotes
neurogenesis in the olfactory epithelium [267]. The transcriptome of the olfactory
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epithelium is consistent with increased oxidative stress, apoptosis, and decreased
neurogenesis.

1.15 Disease progression timeline in hq mice
As a result of Aif down-regulation, hq mice can be distinguished from WT mice at
birth due to decreased body mass that persists into adulthood, as well as patchy or no hair
growth, and minimal accumulation of intraperitoneal fat stores [233]. Deficits in retinal
function and loss of cells from multiple retinal layers are evident by four months of age
[232]. Ataxia onset, an unsteady gait, and lateral tremor are observed at five months of
age [268]. At six months of age, hq mice have increased levels of oxidative stress and
apoptosis in the olfactory epithelium [245]. By seven months of age, necrotic Purkinje
cells are evident and there is a significant decrease in the size of the cerebellum [232].
Complete vision loss is reported for 10-month-old hq mice [232, 269]. The hq phenotype
demonstrates the effects of mitochondrial dysfunction and neurodegeneration.

1.16 The hq mouse is not specifically a model of Alzheimer’s Disease, Parkinson’s
Disease, or Amyotrophic Lateral Sclerosis
The most obvious difference between neurodegeneration in hq mice and
neurodegeneration in AD, PD, and ALS is the location of neurodegeneration. In hq mice
neuron loss is limited to the retina and the cerebellum whereas in AD, PD, and ALS
neuron loss occurs in the neocortex, limbic system, basal ganglia, or spinal cord.
Individuals with AD lose neurons in the entorhinal cortex [10], hippocampus [270],
motor cortex, and sensory cortex [271]. Individuals with PD lose dopaminergic neurons
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in the substantia nigra [272] and those with ALS lose upper and lower motor neurons in
the frontal cortex and spinal cord [273, 274]. The pathological features in AD, PD, and
ALS are also different compared to those seen in hq mice. In individuals with AD, the
brain contains amyloid

plaques and neurofibrillary tangles comprised of

hyperphosphorylated tau protein [275]. In PD, the brain contains Lewy bodies [276], and
in ALS diseased brains, the motor neurons contain Lewy body-like inclusions [277],
skein-like inclusions [278], and Bunina bodies [279]. Hyperphosphorylated tau protein is
not elevated in hq mice compared to WT mice [280], but levels of amyloid

plaques,

Lewy bodies, Lewy body-like inclusions, skein-like inclusions, and Bunina bodies have
not been studied in hq mice. Although cerebellar degeneration of hq mice does not
strictly resemble neurodegeneration in AD, PD, and ALS, neurodegeneration in hq mice
does share common mechanisms with AD, PD, and ALS. These mechanisms include
disturbances in movement, increased oxidative stress, mitochondrial dysfunction,
inflammation, and a progressive loss of neurons with age. Thus, hq mice share features
that are in common with AD, PD, and ALS and can permit the examination of the
neurodegenerative processes that are common to all.

1.17 Hormesis as an anti-aging strategy
Hormesis is a potential anti-aging strategy with a long history in lifespan
extension and cancer prevention, but very little has been studied in the context of
neurodegeneration. In hormesis, low doses of a stressor stimulates resistance to that
stressor and are beneficial to an organism [281]. Hormesis has been studied in a variety
of different organisms with different stressors. Seedlings of Vicia faba (fava beans)
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exposed to low doses of lead in the soil grew taller [282]. The low doses of lead induced
expression of heat shock proteins, as well as antioxidant enzymes to produce an enhanced
defense against oxidative stress [282]. In Drosophila, low doses of ethanol increases the
longevity in three different strains [283]. This increase in Drosophila lifespan could be
due to elevated levels of sirtuin mRNA which is increased after ethanol feeding [284].
Exposure of C. elegans to a low dose of juglone, a chemical that stimulates oxidative
stress, increases survival by 23% when exposed to lethal doses of juglone and juglone
produces cross-tolerance to a different oxidative stressor [285]. In another study using an
oxidative stressor in C. elegans, pretreatment with high concentrations of oxygen
increases survival from X-irradiation through increases in the expression of heat shock
proteins [286], suggesting that a single stressor can induce resistance to different
stressors. Mallards (Anas platyrhynchos) that consume a diet with low concentrations of
mercury exhibit enhanced hatching success and increased mean weights of six-day-old
ducklings [287]. Caloric restriction increases the lifespan of animals by preventing
diseases associated with age including cancer [288], diabetes [289], obesity [288, 289],
and cardiovascular disease [289]. Gene expression in calorically restricted mice reveals
decreased expression of genes involved in immunity, defence, and inflammation [200,
202, 290, 291]. In a mouse model of retinitis pigmentosa, low-dose radiation delays
retinal loss due to up-regulation of the peroxdoxin-2 gene, which is an antioxidant
enzyme [292]. Voluntary exercise on the running wheel is not able to reduce amyloid
and tau accumulation in 3xTg-AD mice but is able to reduce lipid peroxidation, as well
as increase glutathione peroxidase to levels seen in control mice [293]. Long-term
endurance exercise improves movement, balance, mitochondrial function, and prevents

34
loss of dopaminergic neurons in the substantia nigra in a mouse model of PD [294]. Two
ppm of phenobarbital (PB) decreases the amount of liver cancer in rats treated with Ndiethylnitrosamine, a potent inducer of hepatocarcinoma [295]. Aside from studies of
caloric restriction and exercise and their effects on lifespan extension and
neurodegeneration, other hormetic agents have not yet been studied in a mouse model of
neurodegeneration.

1.18 Phenobarbital as a hormetic agent
Phenobarbital is a barbiturate commonly used to treat epilepsy in humans.
Phenobarbital binds the -aminobutyric acid (GABAA) receptor, allowing chloride ions to
enter neurons causing hyperpolarization and suppression of neuronal activity [296-298]
and locomotor activity [299]. Cases of increased physical activity are also observed with
PB administration [299, 300]. Phenobarbital is known to target neurons in the cortex,
hypothalamus, limbic system, caudate nucleus, cervical spinal cord, trigeminal ganglion,
and the cerebellum [301]. Treatment of pregnant mice with high doses of PB leads to
structural abnormalities in the cerebellum of the offspring, in particular to the
mitochondria, myelin sheaths, and lamellar bodies of the granule cell layer [302].
Phenobarbital is a known tumour promoter in rodents [303-306] but is considered to be a
weak mutagen, since in the absence of liver microsomal enzymes, PB induces only a twofold increase in mutations in Salmonella typhimurium straim TA 1535 [307, 308] and is
negative in strains TA98, TA100, TA1537, and TA1538 [309, 310]. However, in vivo
studies using the Big Blue mouse transgenic mutation detection assay, PB is not able to
increase the frequency of mutations at a dose of 2500 ppm but is able to change the
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mutation spectra of mutation types [305, 306]. Phenobarbital would be of use as a
hormetic agent since at high doses, PB inhibits locomotor activity, causes structural
damage to the cerebellum, changes mutation spectra, and is a known promoter of liver
tumours in rodents [303-306], but at low doses PB increases locomotor activity [300] and
prevents liver cancer in a rat model of hepatocarcinoma [295]. Low doses of PB in the
range of 1 to 7.5 ppm reduced the number of preneoplastic lesions in rats injected with
diethylnitrosamine [311]. The molecular mechanisms underlying the hormetic effects of
different stressors have not been elucidated, but in the case of the rat model of
hepatocarcinoma, 2 ppm of PB decreases the amount of 8-hydroxy-2'-deoxyguanosine (8OHdG), a marker of oxidative DNA damage, through the up-regulation the of 8-OHdG
repair enzyme Oxoguanine glycosylase-1 [295]. Phenobarbital also suppresses cellular
proliferation and apoptosis in the liver through decreased expression of Mitogen activated
protein kinase p38 as well as other kinases [295].
Hormesis has thus demonstrated success as an anti-aging and anti-carcinogenesis
strategy and PB has demonstrated success in vivo with anti-carcinogenesis. If the
mechanisms by which PB is able to reduce hepatocarcinoma are similar to the
mechanisms demonstrated in exercise and caloric restriction in anti-aging, then PB
should be successful as an anti-aging strategy in the hq mouse, a model of
neurodegeneration. We know that 2 ppm of PB reduces ROS-induced DNA damage and
increases DNA repair [295], while the hq mouse has elevated ROS-induced mutations
[241], and neurodegenerative diseases have elevated DNA damage in nuclear and
mitochondrial DNA [40]. Neuronal cells have reduced base-excision repair [203] and
DNA repair was decreased in fibroblast and lymphoblastoid cell lines from individuals
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with neurodegenerative diseases [312, 313]. Since both cancer and neurodegeneration
display increased ROS, DNA damage, and decreased DNA repair, then it could be
hypothesized that PB would prevent neurodegeneration even though PB hormesis has not
been demonstrated in an anti-aging capacity.

1.19 Phenobarbital metabolism in mice
Phenobarbital is metabolized and inactivated in the liver. The metabolism of PB
occurs in two phases. In the first phase, PB undergoes hydroxylation by the cytochrome
P450 monooxygenases, producing p-hydroxyphenobarbital [314, 315]. In the second
phase, PB and p-hydroxyphenobarbital can be conjugated with glucuronic acid (Nglycoslyation) by the mircosomal enzyme glucuronyl transferase to produce PB Nglucuronides and p-hydroxyphenobarbital O-glucuronides respectively [316-318]. In
addition, PB can be conjugated with glucose (N-glucosylation) by the enzyme glucosyl
transferase to produce PB N-glucosides [319-321]. Once PB is hydroxylated or
conjugated it is considered inactivated [319, 322]. Phenobarbital enters the brain through
passive diffusion [323] and is eliminated from the kidney through urine, from the liver
through bile, and from the gastrointestinal tract through feces [314]. Urine analysis in
mice shows that most of the PB is eliminated as p-hydroxyphenobarbital followed by
unmetabolized PB, and finally PB N-glucuronides and PB N-glucosides [317]. The halflife of PB in mice is 11.5 hours [324]. PB eliminated via the bile can be reabsorbed in
the intestine or eliminated in feces [314, 325, 326].
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1.20 Biomarkers for the assessment of an anti-aging strategy
Behavioural assays can be used as markers to assess cerebellar dysfunction.
Using rotarod, a rotating cylinder suspended above the ground, hq mice display deficits
in balance and coordination [280]. Locomotor assays have been used previously in
mouse models prior to the onset of neurodegeneration [327-329]. However, a global
assessment of nocturnal behaviour would provide insight into different parameters
involved in movement and an automated home cage decreases the amount of time spent
on manual observations while also decreasing observer bias [330]. Mouse models of
cerebellar degeneration, despite having ataxia, display either higher or lower activity
levels when compared to control mice. The Lurcher mutant mouse has higher levels of
activity compared to control mice [227, 331] and spends more time walking and covers
more distance compared to WT mice [331]. The reeler mutant mouse has higher activity
levels but a lower number of rearing events compared to WT control mice [332].
However both weaver [333] and staggerer [334] mutant mice are hypoactive and rear
less compared to control mice. Leaner mutant mice also have decreased motor activity
[335]. An assessment of nocturnal behaviour would also determine whether low-dose
administration of PB is able to target the brain and induce the expected effect of
hyperactivity in WT and hq mice.
Another neurodegenerative assessment marker is tissue pathology. Tissue
pathology can be identified using hematoxylin and eosin staining of tissue sections to
examine tissue structure, architecture, thinning of the granule cell layer, and cell loss of
the Purkinje cell layer. Hematoxylin is a basic dye that binds acidic compounds of the
nuclei a blue/purple, while eosin stains basic compounds in the cytoplasm a red/pink
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[336]. Neuropathology has been assessed previously using hematoxylin and eosin [232,
277], and will give a qualitative assessment of neuron loss. A quantitative measurement
of the number of degenerating neurons can be determined through the use of FluoroJade B staining, a fluorochrome capable of staining apoptotic neurons resulting from
exposure to a variety of different neurotoxic insults [337].
Another marker employed to assess neurodegeneration is the level of ROS in the
cerebellum. The effect of elevated ROS can be examined by measuring the damage to
cellular components including lipids, proteins, and DNA. Damage to lipids and proteins
can be assayed by lipofuscin accumulation. Lipofuscin is a fluorescent pigment
composed of oxidized lipids, proteins, and metals [43, 338] that accumulate with age in
post-mitotic neurons [46-48]. Lipofuscin accumulation is detected in mouse models of
neurodegeneration [339, 340]. Mutation frequency and pattern can be assessed to see if
ROS-associated DNA damage is replicated in the DNA as mutations leading to elevated
mutation load in hq mice. Mutations in the DNA can be determined through the use of
transgenic mutation detection assays. Using the human placental alkaline phosphatase
(PLAP) assay, hq mice have a 3-fold elevation in mutant frequency in the brain and this
is not seen in other tissues in hq or WT mice [241]. However, the PLAP assay is
restricted to the detection of single base pair deletions, which is only one signature of
oxidative stress. Oxidative stress is associated with chromosome loss [341], DNA strand
breaks [342], chromosome rearrangements [343], mitotic recombination [344], large
[345] and small deletions [346], and the induction of point mutations with the most
common being G:C to T:A transversions [347], although other base pair changes are
implicated as well [345, 347]. In contrast to the PLAP assay, a forward mutation
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detection assay such as the cII assay in Big Blue® mice [348] offers analysis of mutation
load using multiple susceptible DNA sequence contexts.
The production of ROS in the form of superoxide anions may be detected using
dihydroethidium (DHE), a dye that fluoresces when oxidized by superoxide anions into
ethidium [349]. Ethidium is a DNA intercalating agent that fluoresces red when excited
by ultraviolet light and is capable of detection with fluorescence microscopy [350].
Levels of superoxide anions in the brain have been assessed by DHE previously [351].
Lastly, microarray technology is a powerful tool that provides researchers with
the opportunity to analyze the level of mRNA of thousands of genes simultaneously
[352]. Gene expression analyses in mouse models of neurodegeneration have implicated
oxidative stress, mitochondrial dysfunction, and inflammatory response [353-357], as
well as mitochondrial dysfunction leading to decreased energy metabolism [358]. The
use of high-density microarrays can identify genome-wide changes in the levels of
mRNA in the mouse cerebellum and can identify altered pathways early in the
neurodegeneration process.

1.21 Central hypothesis and Experimental Aims
Given that cancer and neurodegenerative diseases are associated with elevated
DNA damage and decreased DNA repair and given that hormesis has demonstrated
efficacy as an anti-carcinogenesis strategy in a mouse model of hepatocarcinoma, I
hypothesize that chronic low doses of PB treatment in hq mice will delay cerebellar
neurodegeneration.
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Given that cerebellar function is required for coordinated movement, I
hypothesize that hq mice will have decreased nocturnal behaviours compared to WT
mice. In addition, given that PB administration increases activity in rodents, I
hypothesize that PB administration will limit age-related decreases in nocturnal
behaviours in hq mice through mechanisms that will reduce cerebellar degeneration.
Three age groups will be tested, representing three stages in the progression of cerebellar
degeneration in hq mice. Three months of age represents early disease onset, 7 months of
age represents mid-disease onset, and 10 months of age represents late-stage disease.
Mice at 3 and 7 months of age will be administered 0, 2, or 4 ppm of PB in the drinking
water ad libitum. Nocturnal behaviours will be measured overnight. I predict that hq
mice will have cerebellar deficits leading to decreased nocturnal activity compared to WT
mice and the nocturnal activity will decrease with age. I also predict that PB will reverse
age-related declines in nocturnal behaviours and that it will increase nocturnal activity in
WT mice, given the evidence reported to date.
Given that hq mice are undergoing cerebellar neurodegeneration, I hypothesize
that there will be an increase in cell loss, apoptosis, lipofuscin accumulation, and
superoxide anion levels compared to WT mice. In addition, given that PB administration
affects different anti-aging pathways, I hypothesize that hormetic PB administration will
limit cell loss, apoptosis, lipofuscin accumulation, and superoxide anion levels.
Hematoxylin and eosin histological assessments will be used to look at cerebellum size,
structure, and evidence of cell loss in the granule and Purkinje cell layers. In situ FluoroJade B staining will be used to assess the number and location of neurons undergoing
apoptosis. The accumulation of damaged cellular components in the form of lipofuscin
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will be assessed. The amount of superoxide anions will be measured to determine
whether increased ROS is associated with cerebellar neurodegeneration in hq mice. I
predict that hq mice will have smaller cerebella and increased cell loss of the granule and
Purkinje cell layers over time. In addition, I predict that biomarkers of
neurodegeneration will be elevated in hq mice and will increase with age compared to
WT mice. Phenobarbital treatment is predicted to decrease the biomarkers of
neurodegeneration.
Given that hq mice had an elevated number of single nucleotide deletions in the
whole brain compared to WT mice, I hypothesize there will be an increase in the
spontaneous mutant and mutation frequency of the cII gene and a change in the mutation
pattern in the cerebellum of hq mice when compared to WT mice. The hq mice will be
bred with Big Blue transgenic mice to allow for mutation detection. Spontaneous
mutant and mutation frequency and pattern will be studied in 3- and 7-month-old WT and
hq mice in the absence of PB administration. I predict that hq mice will have an elevated
mutant and mutation frequency when compared to WT mice. In addition, the mutation
pattern will be altered and contain signatures of oxidative stress in hq mice.
Given that pathways involving oxidative stress, mitochondrial dysfunction, and
inflammation have been detected in neurodegenerative disorders, I hypothesize that hq
mice will have altered pathways involved in oxidative stress, mitochondrial dysfunction,
and inflammation when compared to WT mice. Also, given that PB administration may
affect anti-cancer pathways, I hypothesize that PB administration will counteract
oxidative stress, mitochondrial dysfunction, and inflammation in hq mice. Gene
expression in hq and WT mice will be assayed prior to onset of cerebellar degeneration at
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3 months of age. I predict that hq mice will have down-regulated gene expression in
pathways involved in cellular repair and up-regulated genes involved antioxidant
response, mitochondrial dysfunction, and inflammation when compared to WT mice and
that PB administration will up-regulate genes involved in cellular repair or down-regulate
genes involved in mitochondrial dysfunction and inflammation.
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CHAPTER TWO – MATERIALS AND METHODS

2.1 Animals
2.1.1 General care
Animal protocols were approved by The Animal Use Subcommittee of the
University Council on Animal Care of The University of Western Ontario (Appendix A).
All mice were housed two or three in a cage on a 12 h light/dark cycle at a constant
temperature of 21 ± 1°C and relative humidity of 44 to 60%. Mice were fed a standard
diet (PMI Foods, St. Louis, MO) ad libitum. All experimental mice were male and either
wild type (WT) for the Aif gene or harlequin (hq; B6CBACa Aw-J/A-Pdcd8Hq/J; Bar
Harbor, Maine).

2.1.2 Hormetic treatment
Mice of both genotypes were given phenobarbital (PB) (Sigma-Aldrich, St. Louis,
MO) in concentrations of 2 or 4 ppm administered in the drinking water provided ad
libitum from 1 month of age until euthanized at 3 or 7 months of age. Drinking water
intake was measured everyday for a three-week period for a subset of mice at 7 months of
age. This was done to determine the amount of water consumed (mL/g/day) for each
genotype and to confirm no PB taste aversion. A two-factor Analysis of Variance
(ANOVA) for genotype and treatment was performed on the amount of water consumed
in WT and hq mice with and without PB treatment.
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2.1.3 Breeding hq/Big Blue transgenic mice for transgene mutation detection and
increased inbred mouse background
Four-month-old heterozygous female hq (XhqX) mice (B6CBACa Aw-J/APdcd8Hq/J; The Jackson Laboratory, Bar Harbor, ME), were bred to 3-month-old male
Big Blue® mice (C57Bl/6) homozygous for the lambda phage cII transgene (Taconic
Farms, Germantown, NY) in order to incorporate the cII mutation detection target in hq
mice (Figure 2.1). The first generation progeny were either WT (XY or XX) or had the
hq mutation (XhqY or XhqX) and all mice were hemizygous for the cII transgene (cII/0)
and were brother and sister mated to generate additional mice with both the hq
mutation and the cII transgene. This mating strategy produced an increased number of
mice having hydrocephaly and microphthalmia, due to the background of C57Bl/6J mice
[359, 360]. As a result, both male and female progeny from the second generation were
bred with inbred CBA/CaJ mice (The Jackson Laboratory, Bar Harbor, ME). The
inbreeding of hq mice to the CBA/CaJ background continued for a total of four
generations. Additional brother to sister matings were performed for three more
generations to increase the number of male mice with the hq mutation and the
(hemizygous or homozygous) presence of the cII transgene. The zygosity of Big Blue®
mice for the cII gene does not affect the spontaneous mutant or mutation frequencies
[361]. Mice used in this study were male WT mice (XY) or hemizgyous hq mice (XhqY)
from generations four through nine (G4 – G9) with 75 to 94% CBA/CaJ inbred mouse
background.
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Figure 2.1 - The harlequin (hq) mouse breeding strategy

Figure 2.1 – The harlequin (hq) mouse breeding strategy. Heterozygous hq female
mice (XhqX; B6CBACa) were initially bred with Big Blue® transgenic mice (C57Bl/6J)
homozygous for the cII transgene. The offspring were brother and sister mated (G1) to
increase the number of hq mice with the cII transgene. Mice from this generation were
mated with CBA/CaJ inbred mice and this breeding strategy continued for four
generations (G2 - G5) in order to decrease the genetic variability in the mice on a
primarily CBA/CaJ background. Additional brother and sister matings were performed
to increase the number of hq male mice with the cII mutation target (G6 - G8).
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2.1.4 Genotyping of WT and hq mice
Animals were ear notched and tail clipped at 10 to 12 days of age and DNA was
extracted using a small-scale genomic DNA extraction protocol. Tail clippings were
digested overnight at 55ºC in TENS buffer and Proteinase K (Invitrogen, Burlington,
ON). After digestion, the suspension was transferred to a 1.5 mL Phase Lock Gel™ tube
(Qiagen, Mississauga, ON) with an equal volume of a 50:50 phenol:chloroform mix. The
suspension was centrifuged for 5 min at 14,000 rpm. The aqueous layer was transferred
to a clean 1.5 mL Eppendorf tube. DNA was precipitated with 100% ethanol and
centrifuged at 14,000 rpm for 10 min. The supernatant was decanted and the pellet was
allowed to air dry. The pellet was dissolved in 30 l of TE buffer. DNA was stored at
4ºC until used for genotyping the cII and Aif gene.
The presence of the cII sequence in Big Blue® mice was detected using polymerase
chain reaction (PCR) amplification. A 476 bp sequence containing the cII gene was
amplified using the primer set ASPCIIF 38248: 5’ CCG CTC TTA CAC ATT CCA GC
3’ and JAKCIIR 38723: 5’ CCT CTG CCG AAG TTG AGT AT 3’ [362]. PCR was
performed with the following conditions: 1.2 g of sample DNA, 0.32 mM dNTP, 1X
PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl) 2 mM MgCl2, 0.08 µM of each
primer, and 0.02 U/µl Taq DNA polymerase in a 30 µl reaction volume. The reaction
consisted of an initial denaturation at 94ºC for 5 min, followed by 35 cycles of template
denaturation at 94°C for 20 sec, primer annealing at 53°C for 80 sec, primer extension at
72ºC for 2 min, with a final primer elongation at 72°C for 10 min (GeneAmp PCR
System 9600, Applied Biosystems, Foster City, CA).
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The Aif genotype was determined by PCR amplification using a tri-primer protocol
[232]. The forward, Aif 3468 5’ AGT GTC CAG TCA AAG TAC CGG G 3’ and
reverse, Aif 4000 5’ CTA TGC CCT TCT CCA TGT AGT T 3’ primers were designed
for exons one and two respectively of the Aif gene. Another forward primer was
designed from the long terminal repeat of the murine C-type ecotropic virus hqLTR2 5’
GAA CAA GGA AGT ACA GAG AGG C 3’located in intron one of the Aif gene in hq
and carrier mice. PCR was performed with the following conditions 1.2 g of sample
DNA, 0.32 mM dNTP, 1X PCR buffer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3.5 mM
MgCl2, 0.08 µM of each primer, and 0.02 U/µl Taq DNA polymerase in a 30 µl reaction
volume. Cycling conditions included an initial denaturation at 94ºC for 3 min, followed
by 35 cycles of 94ºC for 30 sec, 62ºC for 1 min, 72ºC for 1 min, followed by 72ºC for 2
min (GeneAmp PCR System 9600, Applied Biosystems, Foster City, CA).

2.2 The experimental cohorts
The experimental design consisted of 152 mice from G4 – G9, with 70 WT (XY)
and 82 hq (XhqY) mice (Figure 2.2). The mice were further divided into three groups
according to age; 3 months of age (WT n=29, hq n=35), 7 months of age (WT n=32, hq
n=38) and 10 months of age (WT n=9, hq n=9). Each genotype was administered 0, 2,
and 4 ppm of PB in the drinking water provided ad libitum from 1 month of age until
euthanized at 3 or 7 months of age. The control cohorts of mice received untreated
drinking water ad libitum. Mice were euthanized according to the standard operating
procedure (protocol# 320-02) at 3, 7, or 10 months of age by CO2 inhalation and mouse
body mass was recorded.
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Figure 2.2 - Experimental design used to assess cerebellar degeneration and a potential intervention
strategy using phenobarbital (PB).

Figure 2.2 – Experimental design used to assess cerebellar degeneration and a
potential intervention strategy using phenobarbital (PB). The experimental design
included 152 male mice, 70 wild type (WT) and 82 harlequin (hq) mice. The mice were
further divided into three different age groups representing three different disease time
points. Mice at 3 months of age represent the early disease time point, mice at 7 months
of age represent the mid-disease time point, and mice at 10 months of age represent the
late stage of the disease time point. In the 3 and 7 months of age cohorts, mice were
treated with 0, 2, or 4 ppm of PB. The untreated cohorts received drinking water ad
libitum and the treated cohorts received 2 or 4 ppm of PB dissolved in the drinking water
ad libitum. Cerebellar function and response to PB were assessed by monitoring
nocturnal cage behaviour. Postmortem in situ histopathology assays were performed on
the cerebellum to determine changes with disease progression. Mutation detection with
the cII transgene mutation detection assay was performed on the cerebellum to determine
whether mutations were elevated and accumulated with age in the cerebellum of hq mice
compared to age-matched WT mice. Gene expression analysis was performed to
determine early changes in gene expression associated with the hq genotype.
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2.3 Behaviour testing of WT and hq mice
Mouse behaviour was recorded using the ActiTrack® apparatus and software
(Panlab Harvard Apparatus, Barcelona, ES) in a mouse test cage that simulates the home
cage environment. Eleven different parameters of mouse movement were quantified
using the ActiTrack® system: activity, locomotion, stereotypes, distance, resting time,
time spent moving slowly, time spent moving quickly, maximum velocity, mean velocity,
number of rearings, and mean rearing duration, as they best characterized mouse
behaviour (Table 2.1). Each mouse was placed individually into a clear plastic test cage
measuring 14.7 inches deep x 9.2 inches wide x 5.5 inches high (Innovive, San Diego,
CA), which was similar in size to a home cage, with a thin layer of cedar shavings
(Nepco, Warrensburg, NY). Five to six food pellets were placed in one corner and water
(containing 0, 2, or 4 ppm PB as per the animal treatment cohort study) was made
available overhead ad libitum. Mouse access to the water bottle does not register as a
rearing event because the upper infrared beam that records movement in the z-axis is
higher than the water bottle spout. No nestlet material was provided to avoid interference
with the infrared beams used to track mouse movement in the ActiTrack ® apparatus. The
test cage was assembled and the mouse placed into the testing arena at 1400 hours, 4
hours before testing was started to allow familiarization with the new environment. The
threshold values for velocity were set so resting was defined as any movement less than 2
cm/s, moving slow as any movement between 2 cm/s and 5 cm/s, and moving fast was as
any movement above 5 cm/s [363]. Rearings were measured when the mouse stood on
its hind legs and blocked the infrared beams of the upper grid in the arena. The upper
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Table 2.1 Description of the behaviours measured in wild type and harlequin mice using the
ActiTrack apparatus
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beam was adjusted according to the mouse body size, which was empirically determined,
to ensure the mouse was able to trigger the upper beam. Daylight and nocturnal
behaviour were recorded at hourly intervals beginning at 1800 hours until 2000 hours and
2000 hours to 0300 hours, respectively. Behaviour was studied for two consecutive
nights for each mouse and analyses were performed on overnight data for WT and hq
mice at 3 months of age (n=9 WT and n=14 hq mice, no drug treatment; n=10 WT and hq
mice, 2 ppm PB; n=10 WT and n=11 hq mice, 4 ppm PB), 7 months of age (n=9 WT and
n=12 hq disease mice, no drug treatment; n=12, WT and hq mice, 2 ppm PB; n=11 WT
and n=14 hq mice, 4 ppm PB), and 10 months of age (n=9, WT and hq mice, no drug
treatment).

2.3.1 Statistical analysis of WT and hq mouse behaviour
A principal component analysis (PCA) with varimax rotation and Kaiser
normalization was performed to identify interrelationships between nocturnal test cage
behavior parameters. Missing values were converted to group means for PCA. Factors
with eigenvalues >1 were used for further analysis. A three-factor (genotype, age and
treatment) MANOVA (p<0.05) followed by Tukey’s test for post hoc analysis was used
to compare the 11 parameters of behaviour measured by the Actitrack in WT and hq mice
at 3, 7, and 10 months of age with three different concentrations of phenobarbital 0, 2,
and 4 ppm in the drinking water. One-factor ANOVA (p<0.05) was performed to further
analyze significant interactions found with the three-factor MANOVA, or three-factor
ANOVA. All statistics were performed with Statistical Package for the Social Sciences
(SPSS) Version 17.0 (IBM, Somers, NY).
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2.4 In situ histological assays for neurodegeneration and testing ROS as an underlying
hypothesized mechanism of disease
2.4.1 Mouse tissue collection
Mice were euthanized according to standard operating procedures (protocol# 32002) at 3, 7, and 10 months of age by CO2 inhalation and body mass was recorded. The
whole cerebellum was harvested and either flash frozen in liquid nitrogen for some mice
for use in the cII assay or half of the cerebellum was placed into a cryomold containing
optimal cutting temperature media (Somagen Diagnostics, Edmonton, Alberta) for
cryosectioning and the other half of the cerebellum was flash frozen in liquid nitrogen for
RNA isolation and stored at -80°C until further use. All animals were healthy at the time
of tissue harvest, with a healthy shiny fur coat with no visible wounds and were able to
move and obtain food and water. No gross tissue pathology was observed for any major
organ.

2.4.2 Cryosectioning of the mouse cerebellum
Half of the cerebellum of WT and hq mice was cryosectioned sagittally at a 10
µm thickness, 200-450 µm distal to the midline using a Leica CM350 Cryostat (Leica
Microsystems, Houston, TX), with two sections being placed per slide on a positively
charged poly-L-lysine microscope slide (VWR, Mississauga, ON), and stored at -20˚C.
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2.4.3 Hematoxylin and eosin tissue section staining to assay cerebellar histopathology
including cell loss
Hematoxylin and eosin staining was performed on frozen unfixed cerebellar
tissue. Slides were immersed in 70% ethanol and then stained with hematoxylin for 5
min and rinsed with water until runoff was colourless. Slides were dipped in 500 mL of
70% ethanol containing 5 drops of 1N hydrochloric acid, immersed in tap water, and
immersed in 1% lithium carbonate (BDH Laboratory Supplies, Poole, England). Sections
were counterstained with Eosin Y (Sigma-Aldrich, Oakville, ON) for 30 sec and
dehydrated by rinsing in increasing concentrations of ethanol 50%, 70%, 95%, and 100%,
followed by a wash in fresh 100% ethanol. Slides were then submerged in xylene until
coverslipped (VWR, Mississauga, ON) with Permount® Mounting Media (Ottawa, ON).
Images of the cerebellum were captured at 20X magnification using the Arcturus
Veritas Microdissection System (Molecular Devices, Sunnyvale, CA) to assess the size
and extent of the nature of gross abnormalities. Further imaging was performed at 200X
magnification to quantify the nuclear density. Images at the base and apex of lobules
I/II, III, VIa, IX and X were captured representing four different zones in the cerebellum
[176] (Figure 2.3). Images were converted into grayscale and the threshold was set to
140 to highlight nuclei (Figure 2.4) using ImageJ analysis software (National Institute of
Health, Bethesda, MD). ImageJ quantified the percentage area containing granule cell
nuclei and are representative of cell numbers. Three nuclear count measurements were
taken per image using a 120 x 90 pixel box corresponding to 57.5 m x 43.1 m. Two
independent scorers, blinded to animal cohort identifiers, determined the percentage of
the area containing nuclei to determine granule cell loss.
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Figure 2.3 - An illustration depicting where images were taken in the sagittal hematoxylin and eosin
stained sections of the mouse cerebellum in order to determine the neuron counts in the granule cell
layer of specific lobules

Figure 2.3 – An illustration depicting where images were taken in the sagittal
hematoxylin and eosin stained sections of the mouse cerebellum in order to
determine the neuron counts in the granule cell layer of specific lobules. The images
were taken at the base (B) and apex (A) of lobules I/II, III, VIa, IX, and X representing
four different zones, anterior zone (AZ: lobules, I-V), the central zone (CZ: lobules VI,
VII), the posterior zone (PZ: lobules VIII, IX), and the nodular zone (NZ: lobule X), in
the mouse cerebellum based on the previously reported unique expression of molecular
markers for determining compartmentalization of the cerebellum [176]. Scale bar = 1 mm
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Figure 2.4 - Neuron counting in the granule cell layer in
wild type (WT) and harlequin (hq) mice

Figure 2.4 - Neuron counting in the granule cell layer in wild type (WT) and
harlequin (hq) mice. A) A hematoxylin and eosin image of the apex of lobule I/II of the
cerebellum in 3-month-old WT mice. B) Images were converted into white nuclei on a
black background in ImageJ. White nuclei were calculated and converted into percentage
area occupied by nuclei. Three nuclear counts were made in both the base and apex of
each lobule for two different cerebellar sections. The nuclear counts in the base and apex
were compared with a one-way ANOVA. The nuclear counts in the base and apex were
similar and the average was taken for the six nuclear counts. Nuclear counts were taken
in three different mice per experimental group by two independent observers. Scale bar =
100 µm.
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2.4.4 Purkinje cell counts to assay Purkinje cell loss
Tissue sections were stained with hematoxylin and eosin as in section 2.5.3.
Purkinje cells, based on morphology and location, were counted from the base to the
apex, and from the apex to the base of lobules I/II, III, VIa, IX, and X for two different
sections per mouse (Figure 2.5). The Purkinje cell counts for each section were averaged
together for each mouse. Purkinje cell counts were taken in three different mice per
experimental group.

2.4.5 Fluoro-Jade® B to assay degenerating neurons with paraquat-treated tissue
controls
Frozen and unfixed cryosections were heated on a 45ºC heat block to evaporate
moisture, stained with hematoxylin and eosin (see section 2.4.3), and subsequently
stained with Fluoro-Jade® B as described previously [337]. Hematoxylin and eosin
stained sections were washed in deionized water for 1 min and transferred to 0.001%
Fluoro-Jade® B (Millipore, Temecula, CA) in deionized water with 0.1% acetic acid for
30 min on a rotating platform. Sections were rinsed in water for 3 min and air dried
before immersing in xylene for 5 min and coverslipping using Permount mounting
media (Fisher Scientific, Pittsburgh, PA). Sections were viewed at 200X under the FITC
filter of the Arcturus Veritas® Microdissection System (Molecular Devices, Sunnyvale,
CA). Fluoro-Jade® B positive cells were counted per whole section with a minimum of 2
sections per animal. Positive and negative controls were created by injecting WT mice
with 10 mg/kg of paraquat or a vehicle control [239], since paraquat is known to
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Figure 2.5 – A hematoxylin and eosin image of the cerebellum of a wild type (WT)
mouse indicating the location were the Purkinje cell counts were made. Purkinje
cells were identified by location and morphology and counted in lobules I/II, III, VIa, IX,
and X for two separate sections and the average was calculated for each lobule. There
were three different mice per experimental group. Scale bar = 1 mm.

Figure 2.5 - A hematoxylin and eosin image of the cerebellum of a wild type (WT)
mouse indicating the location were the Purkinje cell counts were made
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degenerate neurons in the substantia nigra [364] and Fluoro-Jade® B is able to stain
paraquat-treated cells [365]. These mice were euthanized 15 days after injection with
paraquat and the cerebrum was fixed in 4% paraformaldehyde, embedded in paraffin wax
(Leica ASP300, Leica Microsystems, Richmond Hill, ON) [239] and sectioned sagittally
at a thickness of 5 μm (Leica RM2255 Microtome, Leica Microsystems) and
deparaffinized in xylene prior to hematoxylin and eosin staining. Hematoxylin, eosin,
and Fluoro-Jade® B staining were performed as described above (Appendix B, Figure
B.1).

2.4.6 Autofluorescence of the cerebellar tissue to assay lipofuscin accumulation and ROS
damage
Frozen and unfixed cryosections were examined for lipofuscin accumulation
through yellow tissue autofluorescence [44] using the FITC filter (Excitation: 455-495
nm; Emission: > 510 nm) of the Arcturus Veritas® Microdissection System (Molecular
Devices, Sunnyvale, CA). Images were captured at 200X magnification and one image
was taken at the apex of each lobule (I/II, III, VIa, IX, and X) of the cerebellum across
two tissue sections for each mouse. All images where set to a threshold of 140 to get rid
of the green autofluorescence and six measurements were taken in the Purkinje cell layer
using a 100 x 50 pixel box to determine the yellow lipofuscin autofluorescence
(Appendix B, Figure B.2). Quantification was performed by two independent scorers,
blinded to animal cohort identifiers, using ImageJ analysis software (National Institute of
Health, Bethesda, MD).
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2.4.7 Dihydroethidium (DHE) staining of cerebellar tissue sections to assess superoxide
anion levels
Dihydroethidium staining was performed on frozen sectioned cerebellar tissue
that was embedded in optimal cutting temperature media. Frozen slides were heated on a
45ºC heat block to evaporate moisture. A negative control was created by pre-treating
the slide with 30 µl of 1000 U/ml superoxide dismutase (SOD, Sigma-Aldrich Canada
Inc., Oakville, ON) for 10 min at room temperature to remove superoxide anions. A
positive control was created by pre-treating the slide with 20 µl of 0.5 M hydrogen
peroxide solution for 5 min at room temperature. The SOD and hydrogen peroxide
solutions were removed before proceeding with DHE staining in a dark room.
Cryosectioned cerebella were treated with 50 µl of 50 µM DHE in dimethyl-sulphoxide
(DMSO) and incubated in a humidified chamber at 37ºC for 30 min [349] (Appendix B,
Figure B.3). Superoxide anions were quantified on the tissue sections using the green
fluorescence filter (Excitation: 503-548 nm; Emission: > 565 nm) on an inverted Zeiss
microscope (Carl Zeiss Incorporated, Toronto, ON) capable of detecting the DHE
emission wavelength of 590 nm. The fluorescent lamp was set to a gain of ‘1’ and
exposure time of 500 ms for all images and analyses. DHE staining has a very short
duration of fluorescence before quenching begins to occur so time to image capture was
consistently restricted to 3 min per section. Images were captured at 200 X magnification
and one image was taken at the apex of lobules I/II, III, VIa, IX, and X representing four
different zones in the cerebellum determined by gene expression173 for two tissue sections
for each DHE treatment and control. Fluorescence intensity was determined in three
regions per image by drawing a 120 x 90 pixel box in ImageJ analysis software (National
Institute of Health, Bethesda, MD). ImageJ quantifies the fluorescence intensity by
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assigning the detected fluorescence a grey scale brightness value, thus it allows one to
measure the DHE fluorescence.

2.4.8 Statistical analysis for in situ cerebellar phenotyping assays to characterize hq mice
and response to PB treatment
Three-factor MANOVA followed by one-factor ANOVAs (p<0.05) were
performed to further analyze statistically significant interactions found with the threefactor MANOVA. Tukey’s test for post hoc comparison was used to determine
differences in mean granule cell and Purkinje neuron counts, mean fluorescence intensity
of lipofuscin and DHE across genotype, age, and drug treatment, with the level of
significance p<0.05. A three-factor ANOVA was used to determine mean differences in
the number of Fluoro-Jade B positive cells across, genotype, age, and drug treatment.
All data were analyzed using SPSS version 17.0 (IBM, Somers, NY).

2.5 The Big Blue® cII assay for mutation detection
To analyze mutations in the cII gene, high molecular weight genomic DNA was
extracted from 50% of the cerebellum (60 mg) of WT mice and the entire cerebellum (90
mg) from hq mice using the RecoverEase™ DNA Isolation Kit protocol (Stratagene,
LaJolla, CA). Tissues were homogenized, digested with Proteinase K and dialyzed in TE
(pH 7.5) at room temperature for 48 hours. DNA was transferred into a sterile
microcentrifuge tube using a flamed glass capillary rod and stored at 4ºC. The Big Blue ®
cII mutation detection assay was carried out using the Transpak ® and the lambda SelectcII™ protocol [366]. Briefly, lambda phage genomes containing the Big Blue ® cII
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construct were excised from extracted genomic DNA from 21 mice and packaged in vitro
to produce virulent lambda phage, used to infect E. coli strain G1250 and plated.

Plates

were incubated under cII mutant selective (24ºC, 40 hours) or nonselective control (37ºC,
24 hours) conditions.
Putative cII mutants were cored using sterile pipette tips and stored at 4ºC in 500
µl of SM buffer containing 5 µl chloroform and were used to reinfect E. coli to confirm
the mutant phenotype under cII mutant selective conditions [366]. Mutants with
confirmed phenotype were cored and placed in 100 μL of sterile TE (pH 7.5) and stored
at -20ºC until needed. Mutant frequency was calculated by dividing the number of
mutant plaques by the total number of plaque forming units (pfu’s) as estimated from the
number of plaques on titer plates incubated under the nonselective temperature condition
[366].
The cII gene was PCR amplified using primers ASPCIIF 38248 and JAKCIIR
38723 [366]. To remove excess primer and unincorporated dNTPs for sequencing, the
amplified PCR products were incubated with 10 U/ l exonuclease I and 2 U/ l shrimp
alkaline phosphatase for 15 min at 37°C followed by heat inactivation at 80°C for 15 min
(USB Corporation, Cleveland, Ohio). Purified products were sequenced at the Robarts
Research Institute (London, ON) with 2 µM of KOHCIIF 38272 cII primer 5’ AAA AAG
GGC ATC AAA TTA AAC C 3’ [366]. Sequences were compared in a multiple
sequence alignment to the WT cII Genbank reference sequence (J02459) [362] and
mutations were analyzed using Seqscape ® v2.0 (ABI) and Sequencher software (Gene
Codes Inc. Ann Arbor, MI). Sequence chromatograms were analyzed by two individuals.
Mutation frequency was obtained for each cerebellar sample and mouse by correcting the
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mutant frequency for recurrent mutations in the same mouse tissue and dividing by the
total pfu’s assayed.
At least five mice were used per experimental group at 3 and 7 months of age.
Three to six estimates of mutant frequency per mouse were made using the Big Blue® cII
assay with an average packaging efficiency of about 130,000 mutation targets assayed.
The experimental design for the Big Blue® cII assay exceeded recommended guidelines
to achieve the statistical power (66 to 88%) necessary to detect as significant a 50%
change in mutant frequency [367-369]. Also, the mutation(s) in each mutant was(were)
identified and clones removed from the estimate of mutation frequency, further reducing
inter-animal variation in the estimate of mutation frequency [370] and further increasing
statistical power. Mutant and mutation frequencies in the cerebellum of WT and hq mice
were analyzed using a two-factor ANOVA (Microsoft Excel 2007 and SPSS, Somers,
NY). The frequency of Class II deletions [i.e., >1 bp but < 1 kb] [371] in the cerebellum
of young hq mice was compared to the other mouse cohorts in this study and to our
database of cII mutations in WT and hq mice (Ward, unpublished) [239, 240] using a the
Fisher-Freeman-Halton test in StatXact statistical analysis software (CYTEL Software,
Cambridge, MA). Differences in mutation frequencies were significant if p<0.05. The
mutation pattern, the proportion of eleven different mutations, was analyzed using FisherFreeman-Halton test (Monte Carlo simulation) in the StatXact statistical analysis
software package (CYTEL Software, Cambridge, MA) and was considered significantly
different if p<0.05. The mutation spectrum, a visual representation of all the mutations
in the cII gene, was analyzed by plotting all the mutations on the cII sequence to visualize
areas of mutation hot spots.
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2.6 Gene expression in cerebellar tissues to study early mechanisms of degeneration
and response to PB treatment
2.6.1 RNA isolation and purification for gene expression analysis
Total RNA was extracted from half of the cerebellum of WT and hq mice using 1 mL
Qiazol lysis reagent and homogenized with 20 strokes in a 7 mL dounce homogenizer
with pestle A (Wheaton, Millville, NJ). The remainder of the RNA isolation was
processed using the RNeasy® Mini Kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA). Total RNA was purified with 0.25 volumes of 3 M sodium acetate and 4
volumes of 100% ethanol and left overnight in a -20˚C freezer. RNA was pelleted by
centrifugation at 12,000 xg for 30 min, washed twice in 80% ethanol and centrifuged at
4 C for 30 min at 12,000 xg. The pellet was air dried and resuspended in RNase free
water.
Total RNA purity was determined with spectrophotometric A260/280 and A260/230 ratios
in the range of 2.0-2.2, and 1.8-2.1, respectively with the NanoVueTM (GE Healthcare
Bio-Sciences, Piscataway, NJ). RNA integrity was determined by the presence of
prominent 28S and 18S peaks on an electropherogram using the Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA was used if the RNA integrity
number (RIN) was 8.8 or greater. RNA was stored at -80˚C.

2.6.2 Gene expression assayed by microarray hybridization
Total RNA (100 ng) was used to synthesize mRNA into double stranded cDNA with
T7-Oligo (dT) Promoter Primer (Affymetrix, Santa Clara, CA) followed by an in vitro
transcription with T7 RNA polymerase and biotin-labeled nucleotides to form cRNA
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(Affymetrix GeneChip® user manual, 2005). The cRNA was amplified, fragmented, and
hybridized. Each sample was hybridized to a single GeneChip ® Mouse Gene 1.0 ST
Array (Affymetrix, Santa Clara, CA) containing 770,317 probes corresponding to 28,853
genes to obtain expression data. After hybridization, Streptavidin-Phycoerythrin (SAPE)
solution was used to stain the chip by binding to the biotin molecules and emitting
fluorescence which was detected when scanned. The scanned files containing the raw
expression values from the GeneChip® Mouse Gene 1.0 ST Array were imported into
Partek Genomics Suite v6.5 (Partek Inc, St Louis, MO), normalized using Robust
Multichip Average (RMA) protocols and were log2 transformed and analyzed in an a
two-factor ANOVA to obtain a p-value and a fold change. The GeneChips ® were
processed at the London Regional Genomics Centre (Robarts Research Institute, London,
Ontario, Canada). Initially, genes with a fold change > 2.0 or < -2.0 with a p-value <0.05
were considered to be differentially-expressed, but the conditions were too stringent and
only a handful of genes (<10) met the criteria. The filtering parameters where changed to
genes with a fold change > 1.5 or < -1.5 [372] with a p-value <0.05 to be considered
differentially-expressed.

2.6.3 Pathway analysis of gene expression data
Ingenuity Systems Pathway Analysis ® (IPA®) software version 9 (Ingenuity
Systems, Redwood City, CA) was used to determine which predefined biological
pathways had altered gene expression. A list of the Affymetrix gene identifiers,
corresponding fold changes and p-values were uploaded onto the IPA® website for all the
filtered genes. Each Affymetrix gene identifier was mapped to its corresponding gene in
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the Ingenuity’s database. The canonical pathways analysis identified biological pathways
whose genes were altered so that it may have a significant impact on the pathway. Genes
from the data set that were associated with the canonical pathway in Ingenuity’s database
were considered for further analysis. The significance of the association between the
differentially-expressed genes and the canonical pathway was measured in two ways.
First, a ratio was generated of the number of differentially-expressed genes from the data
set that map to the pathway, divided by the total number of genes in the canonical
pathway. Second, a Fisher’s exact test (IPA, Ingenuity Systems, Redwood City, CA)
was used to calculate a p-value to determine the probability that the association between
the genes in the dataset and the canonical pathway was explained by chance alone.
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CHAPTER THREE - RESULTS

3.1 Wild type (WT) and harlequin (hq) mice consumed the same amount of water
regardless of phenobarbital (PB) concentration
A two-factor analysis of variance (ANOVA) determined that untreated WT and
hq mice consumed similar amounts of water (WT: 0.14

0.04 ml/g/day; hq: 0.16

0.06

ml/g/day) and that there was no taste aversion due to PB treatment (WT 2 ppm: 0.15
0.04; hq 2 ppm: 0.20

0.01; hq 4 ppm: 0.16

0.03 ml/g/day).

3.2. Compared to WT mice, hq mice were smaller and gained less mass with age
A three-factor ANOVA showed that body mass was significantly lower in hq
mice compared to WT mice at all ages (Figure 3.1a; p<0.001). At 3, 7, and 10 months of
age, hq mice weighed 30%, 36%, and 35% less than age-matched WT mice, respectively.
Body mass increased with age in WT and hq mice (p<0.001). However, WT mice had a
faster rate of body mass increase with age, gaining 6.6% of WT body mass per month
compared to 4.9% of hq body mass per month between 3 and 7 months of age.

3.2.1 WT, more so than hq mice, gain mass with PB treatment
Phenobarbital treatment increased body mass in WT and hq mice when compared
to untreated control mice (Figure 3.1b; p=0.007). The rate of body mass increase was
higher in WT mice with 2 ppm and 4 ppm PB treatment, gaining 7.9% and 8.1% of WT
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Figure 3.1 - Mouse body mass increased with age and phenobarbital (PB) treatment for wild type
(WT) and harlequin (hq) mice

Figure 3.1 – Mouse body mass increased with age and phenobarbital (PB) treatment
for wild type (WT) and harlequin (hq) mice. A) Mean final body mass (g) was
determined for WT and hq mice at 3, 7, or 10 months of age. Body mass was lower in hq
mice compared to WT mice at all three ages (p<0.001). Body mass increased with age for
both genotypes (p<0.001). B) Mean final body mass (g) was determined for WT and hq
mice at 3, 7, or 10 months of age with three PB treatments (0, 2, and 4 ppm) at the
younger ages. Body mass increased with PB treatment in WT and hq mice (p=0.007).
Error bars represent ± S.E.M.
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body mass per month compared to 5.6% and 7.0% of hq body mass per month,
respectively. The rate of change in body mass when compared to the untreated WT and
hq mice was 1.3% and 1.5% in WT mice at 2 and 4 ppm, while it was 0.7% and
2.1% in hq mice at 2 and 4 ppm.

3.3. WT and not hq mice were responsive to PB treatment showing increased activity
A three-factor multivariate analysis of variance (MANOVA) indicated a
significant three-way interaction of genotype, age, and treatment in the total amount of
overnight activity (p=0.006; Figure 3.2). A genotype-treatment interaction (p=0.001)
was also detected as well as the main effects of genotype (p<0.001) and treatment
(p<0.001). Activity was similar for untreated WT and hq mice and did not change with
increased age. Phenobarbital had a different effect on each genotype. In 3-month-old
WT mice, activity increased with PB treatment (p<0.001), with both 2 and 4 ppm
increasing activity (2 ppm: p=0.006; 4 ppm: p<0.001). In 7-month-old WT mice, activity
also increased with PB treatment (p=0.019), but only 2 ppm PB (2 ppm: p=0.017) and not
4 ppm increased activity. In hq mice, PB treatment did not have any effect on activity
levels at either age.

3.3.1 Phenobarbital-treated WT mice had greater locomotion
There was a three-factor interaction of genotype, age, and treatment (p=0.010) as
well as an interaction of genotype and treatment (p=0.002) on the total number of
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Figure 3.2 - Mouse activity increased with phenobarbital (PB) treatment in wild type (WT) but not
harlequin (hq) mice

Figure 3.2 – Mouse activity increased with phenobarbital (PB) treatment in wild
type (WT) but not harlequin (hq) mice. Mean activity (events) over 9 hours was
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB
treatments (0, 2, and 4 ppm). Activity was similar for untreated WT and hq mice and did
not change with aging. Phenobarbital treatment increased activity in WT mice at 3
(p<0.001) and 7 (p=0.019) months of age. At 3 months of age, 2 and 4 ppm of PB
increased activity levels of WT mice (2 ppm: p=0.006; 4 ppm: p<0.001), but at 7 months
of age, only 2 ppm increased the activity levels of WT mice (2 ppm: p=0.017). Error bars
represent S.E.M.
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locomotion events. Each individual factor had an effect on locomotion as well: genotype
(p=0.001), age (p=0.005), and treatment (p<0.001; Figure 3.3). Locomotor activity was
similar for WT and hq mice without any treatment. Increased age did not alter locomotor
activity in WT or hq mice. In WT mice, PB treatment increased locomotion at 3 months
of age (p<0.001). Both 2 and 4 ppm of PB increased locomotion in 3-month-old WT
mice (2 ppm: p=0.004; 4 ppm: p<0.001). At 7 months of age, PB treatment increased
locomotion (p=0.048), but after post hoc analysis 2 and 4 ppm had p-values > 0.05. In hq
mice, locomotion did not change with PB treatment.

3.3.2 Phenobarbital-treated WT mice had more stereotypic movements
An age-treatment interaction was detected for the number of stereotypic
movements (p=0.006; Figure 3.4). Stereotypic movements were similar in untreated WT
and hq mice and there was no change with increased age. Phenobarbital treatment
increased stereotypic movements in 3-month-old WT mice (p=0.026), with 4 ppm of PB
showing a significant increase in the number of stereotypic movements (4 ppm: p=0.042).
However, in 7-month-old WT mice, PB did not increase stereotypic movements.
Phenobarbital treatment had no effect on hq mice at either age.

3.3.3 Phenobarbital-treated WT mice traveled greater distances
An age-treatment interaction was detected for the distance travelled (p=0.018;
Figure 3.5). For untreated WT and hq mice, distance travelled was similar and did not
change with increased age for either genotype. In WT mice, 4 ppm PB
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Figure 3.3 - Mouse locomotion increased with phenobarbital treatment in wild type (WT) but not
harlequin (hq) mice

Figure 3.3 – Mouse locomotion increased with phenobarbital treatment in wild type
(WT) but not harlequin (hq) mice. Mean locomotion (events) over 9 hours was
determined for WT and harlequin (hq) mice in three age groups (3, 7, and 10 months)
with three PB treatments (0, 2, and 4 ppm). Locomotion was similar for untreated WT
and hq mice and did not change with aging. Phenobarbital treatment increased
locomotion in WT mice at both 3 (p<0.001) and 7 (p=0.048) months of age. At 3 months
of age, 2 and 4 ppm of PB increased locomotion levels of WT mice (2 ppm: p=0.004; 4
ppm: p<0.001), but at 7 months of age, after post hoc analysis, 2 and 4 ppm had p-values
>0.05. Error bars represent ± S.E.M.
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Figure 3.4 - Stereotypic behaviour increased with phenobarbital (PB) treatment in wild type (WT)
but not harlequin (hq) mice

Figure 3.4 –Stereotypic behaviour increased with phenobarbital (PB) treatment in
wild type (WT) but not harlequin (hq) mice. Mean stereotypes (events) over 9 hours
was determined for WT and hq mice in three age groups (3, 7, and 10 months) with three
PB treatments (0, 2, and 4 ppm). Stereotypic behaviour was similar for untreated WT
and hq mice and did not change with aging. Phenobarbital treatment increased
stereotypic behaviour in WT mice at 3 (p=0.026) and not 7 months of age. Error bars
represent ± S.E.M.
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Figure 3.5 - Distance travelled increased with phenobarbital (PB) treatment in wild type (WT) but
not harlequin (hq) mice

Figure 3.5 –Distance travelled increased with phenobarbital (PB) treatment in wild
type (WT) but not harlequin (hq) mice. Mean total distance travelled (cm) over 9 hours
was determined for WT and hq mice in three age groups (3, 7, and 10 months) with three
PB treatments (0, 2, and 4 ppm). Distance travelled was similar for untreated WT and hq
mice and did not change with aging. Phenobarbital treatment increased distance travelled
in WT mice at 3 (p=0.010) and 7 (p=0.038) months of age. At 3 months of age, only 4
ppm of PB increased distance travelled in WT mice (4 ppm: p=0.009), and at 7 months of
age, only 2 ppm of PB increased distance travelled (p=0.037). Error bars ±represent
S.E.M.
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increased distance travelled at 3 months of age (treatment: p=0.010; 4 ppm: p=0.009),
and at 7 months of age, 2 ppm of PB increased distance travelled (treatment: p=0.038; 2
ppm: p=0.037). Phenobarbital did not affect distance travelled in hq mice at either age.

3.3.4 Phenobarbital-treated WT mice spent less time resting
There was a significant three-way interaction of genotype, age, and treatment for
the total amount of time spent resting (p=0.004; Figure 3.6). A genotype-age interaction
(p=0.032) and a genotype-treatment interaction (p=0.002) were detected. The individual
factors of genotype (p=0.008) and treatment (p<0.001) also had an effect on the amount
of time spent resting. Untreated WT and hq mice spent a similar amount of time resting
and did not change with increased age. Phenobarbital treatment was associated with
decreased resting time in WT mice at 3 months of age (treatment: p<0.001; 2 ppm:
p=0.033; 4 ppm: p<0.001) and 7 months of age (treatment: p=0.009; 2 ppm: p=0.007).
Phenobarbital treatment had no effect on the amount of time spent resting in 3-month-old
hq mice. Phenobarbital treatment decreased the amount of time spent resting in 7-monthold hq mice (treatment: p=0.038) but after post hoc analysis both 2 and 4 ppm of PB had
p-values > 0.05.

3.3.5 Phenobarbital-treated WT mice spent more time moving
There was a significant three-way interaction in the amount of time spent moving
slowly (p=0.004; Figure 3.7). There was a genotype-age interaction (p=0.006) and a
genotype-treatment interaction (p=0.036) on the amount of time moving slowly. The
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Figure 3.6 - Time spent resting decreased with phenobarbital (PB) treatment in wild type (WT) but
not in harlequin (hq) mice

Figure 3.6 – Time spent resting decreased with phenobarbital (PB) treatment in
wild type (WT) but not in harlequin (hq) mice. Mean time (s) spent resting (moving
<2 cm/s) over 9 hours was determined for WT and hq mice in three age groups (3, 7, and
10 months) with three PB treatments (0, 2, and 4 ppm). The amount of time spent resting
was similar for untreated WT and hq mice and did not change with aging. Phenobarbital
treatment decreased time spent resting in WT mice at 3 (p<0.001) and 7 (p=0.009)
months of age. At 3 months of age, 2 and 4 ppm of PB decreased time spent resting in
WT mice (2 ppm: p=0.033; 4 ppm: p<0.001), and at 7 months of age, only 2 ppm of PB
decreased time spent resting (p=0.007). Phenobarbital did not have any effect on time
spent resting in 3-month-old hq mice, but PB treatment decreased time spent resting in hq
mice at 7 months of age (p=0.038), but after post hoc analysis 2 and 4 ppm of PB had pvalues > 0.05. Error bars represent ± S.E.M.
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Figure 3.7 - Time spent moving slowly increased with phenobarbital (PB) treatment in wild type
(WT) but not in harlequin (hq) mice

Figure 3.7 – Time spent moving slowly increased with phenobarbital (PB) treatment
in wild type (WT) but not in harlequin (hq) mice. The time (s) spent moving slowly
(moving between 2 cm/s - 5 cm/s) over 9 hours for WT and hq mice in three age groups
(3, 7, and 10 months) with three PB treatments (0, 2, and 4 ppm). The amount of time
spent moving slowly was similar for untreated WT and hq mice and did not change with
aging. Phenobarbital treatment increased time spent moving slowly in WT mice at 3
months of age (p<0.001) and 7 months of age (p=0.005). At 3 months of age, 2 and 4
ppm of PB increased the amount of time spent moving slowly in WT mice (2 ppm:
p=0.012; 4 ppm: p<0.001), and at 7 months of age, 2 and 4 ppm of PB also increased the
amount of time spent moving slowly in WT mice (2 ppm: p=0.005; 4 ppm: p=0.037).
Phenobarbital did not have any effect on time spent moving slowly in 3-month-old hq
mice, but PB treatment increased the amount of time spent moving slowly in hq mice at 7
months of age (p=0.025). At 7 months of age, 4 ppm of PB increased the amount of time
spent moving slowly in hq mice (p=0.020). Error bars represent ± S.E.M
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individual factors of genotype (p=0.018) and treatment (p<0.001) had an effect on the
amount of time spent moving slowly. The amount of time spent moving slowly was
similar in untreated WT and hq mice and did not change with increased age for either
genotype. Phenobarbital increased the amount of time spent moving slowly in WT mice
at 3 months of age (treatment: p<0.001; 2 ppm: p=0.012; 4 ppm: p<0.001) and 7 months
of age (treatment: p=0.005; 2ppm: p=0.005; 4 ppm: p=0.037). The amount of time spent
moving slowly in hq mice at 3 months of age was unaltered by PB. However, 4 ppm of
PB did increase the amount of time spent moving slowly in hq mice at 7 months of age
(treatment: p=0.025; 4 ppm: p=0.020).
The time spent moving quickly was influenced by a genotype-treatment (p=0.009)
interaction (Figure 3.8). The individual factor of treatment (p=0.028) also had an effect
on the time spent moving quickly. The amount of time spent moving quickly was similar
in untreated WT and hq mice did not change with increased age in either genotype.
Treatment with 4 ppm of PB increased time spent moving quickly in WT mice at 3
months of age (treatment: p=0.003, 4 ppm: p=0.002). At 7 months of age, 2 ppm of PB
increased time spent moving quickly in WT mice (treatment: p=0.035; 2 ppm: p=0.027).
Treatment with PB had no effect on the amount of time spent moving quickly in hq mice.

3.3.6 Phenobarbital-treated WT mice attained greater maximum and mean velocities
A significant three-way interaction was detected with maximum velocity
(p=0.047; Figure 3.9). There was also a genotype-treatment interaction (p=0.031) effect
on the maximum velocity. Individual factors of genotype (p=0.016) and age (p=0.010)
had an effect on maximum velocity. Maximum velocity was similar for untreated WT
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Figure 3.8 - Time spent moving quickly increased with phenobarbital (PB) treatment in wild type
(WT) but not in harlequin (hq) mice

Figure 3.8 – Time spent moving quickly increased with phenobarbital (PB)
treatment in wild type (WT) but not in harlequin (hq) mice. Mean time (s) spent
moving quickly (moving >5 cm/s) over 9 hours was determined for WT and hq mice in
three age groups (3, 7, and 10 months) with three PB treatments (0, 2, and 4 ppm). The
amount of time spent moving quickly was similar for untreated WT and hq mice and did
not change with aging. Phenobarbital treatment increased time spent moving quickly in
WT mice at 3 months of age (p=0.003) and at 7 months of age (p=0.035). At 3 months of
age, 4 ppm of PB increased the amount of time spent moving quickly in WT mice
(p=0.002), and at 7 months of age, 2 ppm of PB increased the amount of time spent
moving quickly in WT mice (p=0.027). Error bars represent ± S.E.M

91

.

92

Figure 3.9 - Maximum velocity increased with phenobarbital (PB) treatment in wild type (WT) mice
but not in harlequin (hq) mice

Figure 3.9 – Maximum velocity increased with phenobarbital (PB) treatment in wild
type (WT) mice but not in harlequin (hq) mice. Mean maximum velocity (cm/s) over 9
hours was determined for WT and hq mice in three age groups (3, 7, and 10 months) with
three PB treatments (0, 2, and 4 ppm). Maximum velocity was similar for untreated WT
and hq mice and did not change with aging. Phenobarbital treatment increased maximum
velocity in WT mice at 3 months of age mice (p=0.006) but not at 7 months of age. Error
bars represent ± S.E.M.
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and hq mice and there was no change with increased age. In WT mice, PB treatment
increased maximum velocity at 3 months of age (treatment: p=0.006; 4 ppm: p=0.005),
but there was no change with maximum velocity with PB treatment at 7 months of age.
Phenobarbital did not affect maximum velocity in hq mice at either age.
Mean velocity was influenced by a significant age-treatment interaction (p=0.016;
Figure 3.10). There was no difference in mean velocity between WT and hq mice and
mean velocity did not change with age for either genotype (Figure 3.10). Treatment with
4 ppm of PB increased mean velocity in 3-month-old WT mice (treatment: p=0.010; 4
ppm: p=0.010). At 7 months of age, 2 ppm of PB increased mean velocity in WT mice
(treatment: p=0.043; 2 ppm: p=0.043). Phenobarbital treatment did not affect mean
velocity in hq mice for either age.

3.3.7 Phenobarbital-treated WT mice reared more but the duration of the events was
unchanged
No interactions were detected in the number of rearings with a three-way
MANOVA but two of the main factors had an effect on the number of rearings: genotype
(p=0.009), and age (p=0.026; Figure 3.11). There was no difference in the number of
rearing events in untreated WT and hq mice and age did not affect the number of rearing
events in either genotype. Both 2 and 4 ppm of PB increased the number of rearing
events in WT mice at 3 months of age (treatment: p=0.006; 2ppm: p=0.019; 4 ppm:
p=0.008) but PB did not have an effect on the number of rearing events at 7 months of
age. Phenobarbital had no effect on the number of rearing events in hq mice at either
age. There was no difference in mean duration of rearing events for genotype, age, or PB
treatment (Figure 3.12).
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Figure 3.10 - Mean velocity increased with phenobarbital (PB) in wild type (WT) mice but not in
harlequin (hq) mice

Figure 3.10 - Mean velocity increased with phenobarbital (PB) in wild type (WT)
mice but not in harlequin (hq) mice. Mean velocity (cm/s) over 9 hours was
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB
treatments (0, 2, and 4 ppm). Mean velocity was similar for untreated WT and hq mice
and did not change with aging. Phenobarbital treatment increased mean velocity in WT
mice at 3 months of age mice (p=0.010) and at 7 months of age (p=0.043). At 3 months
of age, 4 ppm of PB increased mean velocity in WT mice (p=0.010) and at 7 months of
age, 2 ppm of PB increased mean velocity in WT mice (p=0.043). Error bars represent ±
S.E.M.

96

97

Figure 3.11 - Rearing behaviour increased with phenobarbital (PB) treatment in WT but not
harlequin (hq) mice

Figure 3.11 – Rearing behaviour increased with phenobarbital (PB) treatment in
WT but not harlequin (hq) mice. Mean number of rearings (events) over 9 hours was
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB
treatments (0, 2, and 4 ppm). Rearings behaviour was similar for untreated WT and hq
mice and did not change with aging. Phenobarbital treatment increased the rearing
behaviour in WT mice at 3 months of age (p=0.006) but not at 7 months of age. At 3
months of age, 2 and 4 ppm of PB increased the rearing behaviour (2ppm: p=0.019; 4
ppm: p=0.008). Error bars represent ± S.E.M.
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Figure 3.12 - Rearing duration showed no effect of genotype, age, or phenobarbital (PB) treatment

Figure 3.12 – Rearing duration showed no effect of genotype, age, or phenobarbital
(PB) treatment. Mean rearing duration (s) over 9 hours was determined for wild type
(WT) and harlequin (hq) mice in three age groups (3, 7, and 10 months) with three PB
treatments (0, 2, and 4 ppm). Error bars represent ± S.E.M.
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. 3.4. Smaller cerebella were characteristic of PB-treated and untreated hq mice
A three-factor analysis of variance (ANOVA) showed a main effect of genotype
(p=0.001) on the mass of the cerebellum, and that the cerebellar mass did not change with
age or PB treatment in WT or hq mice. One-way ANOVA also confirmed that the hq
cerebella had a significantly smaller mass at 3, 7, and 10 months of age when compared
to age-matched WT mice (p=0.001; Figure 3.13a). A three-way ANOVA for the ratio of
the cerebellar mass to body mass showed a main effect of age (p<0.001). The cerebellar
mass to body mass ratio was similar in WT and hq mice and decreased with age for each
genotype (WT: p<0.001; hq: p=0.009; Figure 3.13b). For both genotypes, the cerebellar
mass to body mass ratio decreased at 7 and 10 months of age when compared to mice at 3
months of age (WT 7 months: p=0.001; WT 10 months: p=0.001; hq 7 months: p=0.009;
hq: 10 months: p=0.031). The hq cerebellum is visibly smaller at 7 and 10 months of age
when compared to age-matched WT controls (Figure 3.14). Phenobarbital did not have
an effect on the mass of the cerebellum in WT or hq mice (Figure 3.15; Figure 3.16).

3.4.1 Lobule specific early loss of granule neurons progressed across hq cerebella
unaffected by PB treatment
A three-factor MANOVA was performed on the nuclear counts of the granule cell
layer in WT and hq mice at three different ages with PB treatments and detected a
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Figure 3.13 - Cerebellar mass is lower in harlequin (hq) mice but the cerebellar mass to body mass
ratio is similar to wild type (WT) mice at all ages.

Figure 3.13 – Cerebellar mass is lower in harlequin (hq) mice but the cerebellar
mass to body mass ratio is similar to wild type (WT) mice at all ages. A) WT mice
had a greater cerebellar mass at all three ages (p<0.001) and cerebellar mass did not
change with age or phenobarbital (PB) treatment in either genotype. B) The cerebellar
mass to body mass ratio was similar in WT and hq mice and decreased with age in both
genotypes (p<0.001). Five mice were used per experimental group. Error bars represent ±
S.E.M.
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Figure 3.14 - Histology of the cerebellum in 3-, 7-, and 10-month-old mice displays visible agingassociated cerebellar degeneration in hq mice with age.

Figure 3.14 - Histology of the cerebellum in 3-, 7-, and 10-month-old mice displays
visible aging-associated cerebellar degeneration in hq mice with age. A)
Hematoxylin and eosin staining of a 10 m sagittal section of the cerebellum in 3-monthold WT with Roman numerals indicating cerebellar lobule numbers. B) Hematoxylin
and eosin staining of a 10 m sagittal section of the cerebellum in 3-month-old hq mice
with absence of histopathology. C) An image of the cerebellum from 7-month-old WT
and (D) hq mice with visible loss of the granule cell layer. E) The cerebellum of 10month-old WT and (F) hq mice, where the hq cerebellum remained similar in size to (D)
7-month-old hq mice but is still visibly smaller compared to (E) 10-month-old WT mice.
Scale bars: A-F = 1 mm
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Figure 3.15 - Phenobarbital (PB) had no visible effect on the histology of the cerebellum of wild type
(WT) mice.

Figure 3.15 - Phenobarbital (PB) had no visible effect on the histology of the
cerebellum of wild type (WT) mice. The histopathology of the cerebellum in 3-, and 7month-old WT mice with PB treatment at 0, 2, or 4 ppm was examined. Hematoxylin
and eosin staining of a 10 m sagittal section of the cerebellum in (A) 3-month-old WT
mouse with no PB treatment. Roman numerals indicate cerebellar lobule numbers. B)
An image of 3-month-old WT mouse treated with 2 ppm of PB treatment. C) An image
of 3-month-old WT mouse treated with 4 ppm of PB treatment. D) An image of the
cerebellum from 7-month-old WT mouse with no PB treatment. E) An image of the
cerebellum from 7-month-old WT mouse treated with 2 ppm of PB. F) An image of the
cerebellum from 7-month-old WT mouse treated with 4 ppm of PB. Scale bars: A-F = 1
mm
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Figure 3.16 – Phenobarbital (PB) had no visible effect on the histology of the
cerebellum of harlequin (hq) mice. The histopathology of the cerebellum in 3-, and 7month-old hq mice with PB treatment at 0, 2, or 4 ppm. Hematoxylin and eosin staining
of a 10 m sagittal section of the cerebellum in (A) 3-month-old hq mouse with no PB
treatment. Roman numerals indicate lobule cerebellar numbers. B) An image of 3month-old hq mouse treated with 2 ppm of PB. C) An image of 3-month-old hq mouse
treated with 4 ppm of PB. D) An image of the cerebellum from 7-month-old hq mouse
with no PB treatment. E) An image of the cerebellum from 7-month-old hq mouse
treated with 2 ppm of PB. F) An image of the cerebellum from 7-month-old hq mouse
treated with 4 ppm of PB. Scale bars: A-F = 1 mm
Figure 3.16 - Phenobarbital (PB) had no visible effect on the histology of the cerebellum of harlequin
(hq) mice.
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significant interaction between genotype and age for lobules IX and X (IX: p=0.019; X:
p=0.037). Main effects for genotype and age were also detected in all lobules (genotype,
all lobules: p<0.001; age, I/II: p=0.002; III: p=0.002; VIa: p=0.001; IX: p=0.001; X:
p=0.006; Figure 3.17). At 3 months of age, hq mice had similar nuclear counts for all
lobules studied when compared to WT mice. At 7 months of age, hq mice had
significantly decreased nuclear counts in lobules IX and X when compared to WT mice
(IX: p=0.003; X: p=0.009). At 10 months of age, all lobules examined had a decreased
nuclear count when compared to WT mice (I/II: p=0.004; III: p=0.004; VIa: p=0.009; IX:
p=0.002; X: p=0.001).
The nuclear count did not change with age in WT mice for all lobules studied. In
contrast, the nuclear count decreased with age in hq mice (I/II: p=0.036, III: p=0.012;
VIa: p=0.007; IX: p=0.016; X: p=0.012; Figure 3.17). At 7 months of age, degeneration
was visible in the granule cell layer as hq mice had decreased nuclear counts for lobules
IX and X when compared to 3-month-old hq mice (IX: p=0.045; X: p=0.045). At 10
months of age, all of the lobules studied had decreased nuclear counts (I/II: p=0.042, III:
p=0.028; VIa: p=0.014; IX: p=0.017; X: p=0.013) when compared to hq mice at 3
months of age. Phenobarbital treatment did not have any effect on the nuclear count in
any of the cerebellar lobules in WT or hq mice (Figure 3.17).

3.4.2 Loss of Purkinje cells in hq mice was lobule specific, progressed with age, and was
unaffected by PB treatment
A three-factor MANOVA was performed on the number of Purkinje cells in WT
and hq mice at three different ages with PB treatments detected a significant
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Figure 3.17 - Granule neuron cell counts decreased with age in all lobules examined in
harlequin (hq) mice

Figure 3.17 – Granule neuron cell counts decreased with age in all lobules examined
in harlequin (hq) mice. For all lobules, the granule neuron count did not change with
age in wild type (WT) mice and PB treatment had no effect on the granule neuron count
in either WT or hq mice. A) The nuclear count in lobule I/II of the cerebellum. The
nuclear count was similar for WT and hq mice at 3 and 7 months of age. At 10 months of
age, hq mice had a decreased nuclear count when compared to WT mice (p=0.004). The
nuclear count of lobule I/II decreased with age in hq mice (p=0.036) with decreased
nuclear count in 10-month-old hq mice when compared to 3-month-old hq mice
(p=0.042). B) The nuclear count in lobule III of the cerebellum. The nuclear count was
similar for WT and hq mice at 3 and 7 months of age. At 10 months of age, hq mice had
a decreased nuclear count when compared to WT mice (p=0.004). The nuclear count
decreased with age in hq mice (p=0.012) with decreased nuclear count in 10-month-old
hq mice when compared to 3-month-old hq mice (p=0.028). C) The nuclear count in
lobule VIa of the cerebellum. The nuclear count was similar for WT and hq mice at 3
and 7 months of age. At 10 months of age, hq mice had a decreased nuclear count when
compared to WT mice (p=0.009). The nuclear count decreased with age in hq mice
(p=0.007) with decreased nuclear count in 10-month-old hq mice when compared to 3month-old hq mice (p=0.014). D) The nuclear count in lobule IX of the cerebellum. The
nuclear count was similar for WT and hq mice at 3 months of age. At 7 and 10 months of
age, hq mice had a decreased nuclear count when compared to WT mice (7: p=0.003; 10:
p=0.002). The nuclear count decreased with age in hq mice (p=0.016). In 7- and 10month-old hq mice, the nuclear count was decreased when compared to 3-month-old hq
mice (7 months: p=0.045; 10 months: p=0.017). E) The nuclear count in lobule X of the
cerebellum. The nuclear count was similar for WT and hq mice at 3 months of age. At 7
and 10 months of age, hq mice had a decreased nuclear count when compared to WT
mice (7: p=0.009; 10: p=0.001). The nuclear count decreased with age in hq mice
(p=0.002). In 7- and 10-month-old hq mice, the nuclear count was decreased when
compared to 3-month-old hq mice (7 months: p=0.045; 10 months: p=0.013). Error bars
represent ± S.E.M.
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interaction between genotype and age for lobules I/II, III, VIa, IX, and X (I/II: p=0.006;
III: p=0.002; VIa: p<0.001; IX: p<0.001; X: p=0.002; Figure 3.18). The main effect of
genotype was detected in all lobules, and the main effect of age was detected in lobules
III, VIa, IX, and X (genotype, all lobules: p<0.001; age, III: p<0.001; VIa: p<0.001; IX:
p<0.001; X: p=0.022; Figure 3.18). At 3 months of age, WT and hq mice had a similar
number of Purkinje cells for all lobules studied. At 7 months of age, hq mice had
significantly decreased number of Purkinje cells in lobules III, VIa, IX, and X when
compared to WT mice (III: p=0.001; VIa: p=0.036; IX: p=0.024; X: p=0.025). At 10
months of age, hq mice had a decreased number of Purkinje cells in lobules III, VIa, and
IX when compared to WT mice (III: p=0.017; VIa: p=0.007; IX: p=0.017).
The number of Purkinje cells did not change with age in WT mice for any of the
lobules studied. In contrast, the number of Purkinje cells decreased with age in lobules
I/II, III, VIa, and IX in hq mice (I/II: p=0.010, III: p<0.001; VIa: p=0.006; IX: p=0.014;
Figure 3.18). At 7 months of age, Purkinje cells were reduced in lobules I/II, III, VIa,
and IX when compared to hq mice at 3 months of age (I/II: p=0.021; III: p<0.001; VIa:
p=0.046; IX: p=0.030). At 10 months of age, Purkinje cells were reduced in lobules I/II,
III, VIa, and IX when compared to hq mice at 3 months of age (I/II: p=0.013; III:
p<0.001; VIa: p=0.005; IX: p=0.017). In addition, at 10 months of age, lobule VIa had a
reduced number of Purkinje cells when compared to hq mice at 7 months of age
(p=0.001). Phenobarbital treatment did not have any effect on the number of Purkinje
cells in any of the cerebellar lobules in WT or hq mice (Figure 3.18).
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Figure 3.18 - Purkinje cell numbers were decreased in harlequin (hq) mice

Figure 3.18 – Purkinje cell numbers were decreased in harlequin (hq) mice. For all
lobules the number of Purkinje cells did not change with age in wild type (WT) mice and
PB treatment had no effect on the number of Purkinje cells in WT or hq mice. A) The
Purkinje cell numbers in lobule I/II of the cerebellum. The Purkinje cell number was
similar for WT and hq mice at 3, 7, and 10 months of age. The number of Purkinje cells
decreased with age in lobule I/II in hq mice (p=0.010). At 7 and 10 months of age,
Purkinje cells were significantly decreased when compared to hq mice at 3 months of age
(7 months: p=0.021; 10 months: p=0.013). B) The Purkinje cell numbers in lobule III of
the cerebellum. The Purkinje cell number was similar for WT and hq mice at 3 months of
age. At 7 and 10 months of age, hq mice had decreased numbers of Purkinje cells in
lobule III when compared to WT mice (7 months: p=0.001; 10 months: p=0.017). The
number of Purkinje cells decreased with age in lobule III in hq mice (p<0.001). At 7 and
10 months of age, Purkinje cells were significantly decreased when compared to hq mice
at 3 months of age (7 months: p<0.001; 10 months: p<0.001). C) The Purkinje cell
numbers in lobule VIa of the cerebellum. The Purkinje cell number was similar for WT
and hq mice at 3 months of age. At 7 and 10 months of age, hq mice had decreased
numbers of Purkinje cells in lobule VIa when compared to WT mice (7 months: p=0.06;
10 months: p=0.007). The number of Purkinje cells decreased with age in lobule VIa in
hq mice (p<0.001). At 7 and 10 months of age, Purkinje cells were significantly
decreased when compared to hq mice at 3 months of age (7 months: p=0.046; 10 months:
p=0.005). At 10 months of age, lobule VIa had a decreased number of Purkinje cells
when compared to hq mice at 7 months of age (p=0.001). D) The Purkinje cell numbers
in lobule IX of the cerebellum. The Purkinje cell number was similar for WT and hq mice
at 3 months of age. At 7 and 10 months of age, hq mice had decreased numbers of
Purkinje cells in lobule IX when compared to WT mice (7 months: p=0.024; 10 months:
p=0.007). The number of Purkinje cells decreased with age in lobule IX in hq mice
(p=0.014). At 7 and 10 months of age, Purkinje cells were significantly decreased when
compared to hq mice at 3 months of age (7 months: p=0.030; 10 months: p=0.017). E)
The Purkinje cell numbers in lobule X of the cerebellum. The Purkinje cell number was
similar for WT and hq mice at 3 months of age. At 7 months of age, hq mice had
decreased numbers of Purkinje cells in lobule X when compared to WT mice (7 months:
p=0.025). At 10 months of age, the number of Purkinje cells in WT and hq mice were
similar. Error bars represent ± S.E.M.
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3.4.3 Neurodegeneration was evident in 7-month-old hq mice and unaffected by PB
treatment
A three-factor ANOVA for the number of Fluoro-Jade B positive cells indicated
that there was a significant interaction between genotype and age (p<0.001). At 3 months
of age, WT and hq mice had a similar number of Fluoro-Jade B positive cells (Figure
3.19). At 7 months of age, hq mice had an elevated number of Fluoro-Jade B positive
cells compared to WT mice at 7 months of age (p=0.014). At 10 months of age, WT and
hq mice had a similar number of Fluoro-Jade
of Fluoro-Jade

B positive cells. In WT mice, the number

B positive cells did not change with age. Fluoro-Jade B positive cells

were more numerous at 7 months of age in hq mice when compared to hq mice at 3 and
10 months of age (3 months: p=0.003, 10 months: p=0.002). Phenobarbital treatment had
no effect on the number of Fluoro-Jade B positive cells in WT or hq mice.

3.4.4 Lipofuscin accumulation with age was lobule specific in both WT and hq mice and
unaffected by PB treatment
A three-factor MANOVA on lipofuscin accumulation indicated that there was a
significant genotype and age interaction in lobule III (p=0.049), as well as a genotype
effect in lobules IX and X (IX: p<0.001; X: p=0.012) and age effect in lobules I/II, VIa,
and IX (I/II; p=0.002; VIa: p<0.001; IX: p=0.012). WT and hq mice had a similar
amount of lipofuscin in 3-, 7-, and 10-month-old mice for all lobules despite the reported
genotype effect for lobules IX and X (Figure 3.20).
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Figure 3.19 - There were elevated numbers of dying cells in 7-month-old harlequin (hq) mice.

Figure 3.19 – There were elevated numbers of dying cells in 7-month-old harlequin
(hq) mice. Fluoro-Jade® B positive cells were similar in wild type (WT) and hq mice at 3
and 10 months of age. The number of Fluoro-Jade® B positive cells did not change with
age in WT mice. Fluoro-Jade® B positive cells were elevated at 7 months of age in hq
mice when compared to age-matched WT mice (p=0.014). Fluoro-Jade B positive cells
were elevated at 7 months of age in hq mice when compared to hq mice at 3 and 10
months of age (3 months: p=0.003, 10 months: p=0.002). Phenobarbital had no effect on
the number of Fluoro-Jade® positive cells in WT or hq mice. Error bars represent ±
S.E.M.
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Figure 3.20 - Lipofuscin accumulation was similar in wild type (WT) and harlequin (hq) mice and
increased with age in certain lobules.

Figure 3.20 – Lipofuscin accumulation was similar in wild type (WT) and harlequin
(hq) mice and increased with age in certain lobules. For all lobules PB treatment had
no effect on lipofuscin accumulation. A) The lipofuscin autofluorescence profile in
lobule I/II of the cerebellum. Lipofuscin autofluorescence was similar in WT and hq
mice for all ages studied and PB treatment. Lipofuscin autofluorescence did not change
with age in WT mice. Within hq mice, lipofuscin autofluorescence increased with age in
lobule I/II (p=0.016). Lipofuscin autofluorescence in lobule I/II was elevated in 7- and
10-month-old hq mice when compared 3-month-old hq mice (7 months: p=0.026; 10
months: p=0.023). B) The lipofuscin autofluorescence profile in lobule III of the
cerebellum. The lipofuscin autofluorescence was similar in WT and hq mice for all ages
studied. C) The lipofuscin autofluorescence profile in lobule VIa of the cerebellum. The
lipofuscin autofluorescence was similar in WT and hq mice for all ages studied. In WT
mice, lipofuscin autofluorescence in lobule VIa was elevated with age (p=0.037). At 10
months of age, WT mice had elevated lipofuscin autofluorescence in lobule VIa when
compared to WT mice at 3 months of age (p=0.040). In hq mice, lipofuscin
autofluorescence in lobule VIa was elevated with age (p=0.037), with increased
lipofuscin autofluorescence at 10 months of age when compared to 3 months of age
(p=0.040). D) The lipofuscin autofluorescence profile in lobule IX of the cerebellum.
The lipofuscin autofluorescence was similar in WT and hq mice and did not change with
age. E) The lipofuscin autofluorescence profile in lobule X of the cerebellum. The
lipofuscin autofluorescence was similar in WT and hq mice and did not change with age.
Error bars represent ± S.E.M.
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Lipofuscin accumulated with age in lobule VIa (p=0.037) in WT mice (Figure 3.
20). In lobule VIa, lipofuscin was elevated at 10 months (p=0.040) when compared to
WT mice at 3 months of age. In hq mice, lipofuscin also accumulated with age in lobule
I/II and VIa (I/II: p=0.016; VIa: p=0.037). Lipofuscin in lobule I/II was elevated at 7 and
10 months of age when compared to hq mice at 3 months of age (7 months: p=0.026; 10
months: p=0.023). In lobule VIa, lipofuscin was elevated at 10 months (p=0.040) when
compared to hq mice at 3 months of age. Despite the genotype and age interaction
reported for lobule III, and the age effect for lobule I/II and IX, further analysis with one
way-ANOVA testing both showed no change with genotype or age. Both 2 and 4 ppm
PB had no effect on lipofuscin accumulation in WT and hq mice (Figure 3.20).

3.4.5 ROS increased with age in lobules I/II, III, VIa in both PB-treated and untreated hq
mice
A three-factor MANOVA for DHE fluorescence detected a significant effect of
age in lobules I/II, III, and VIa (I/II: p=0.050; III: p=0.017; VIa: p=0.002). There was no
difference in DHE fluorescence between WT and hq mice at any age in lobules I/II, III,
VIa, XI, and X of the cerebellum (Figure 3.21). In WT mice, the DHE fluorescence did
not increase with age in any lobule. In hq mice, DHE fluorescence was increased at 10
months of age when compared to 3 months of age for lobules I/II, III, and VIa (I/II:
p=0.011; III: p=0.003; VIa: p=0.009). Phenobarbital had no effect on DHE fluorescence
in WT or hq mice.
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Figure 3.21 - The ROS profiles in wild type (WT) and harlequin (hq) mice were similar at all three
ages but ROS did increase with age in hq mice

Figure 3.21 - The ROS profiles in wild type (WT) and harlequin (hq) mice were
similar at all three ages but ROS did increase with age in hq mice. A) The ROS
profile in lobule I/II of the cerebellum. The DHE intensity was similar in WT and hq
mice for all ages studied and PB treatment. The DHE intensity increased at 10 months of
age within hq mice (p=0.011), however it was still not different from WT mice. B) The
ROS profile in lobule III of the cerebellum. The DHE intensity was similar in WT and
hq mice for all ages studied and PB treatment. The DHE intensity increased at 10 months
of age within hq mice (p=0.003), however it was still not different from WT mice. C)
The ROS profile in lobule VIa of the cerebellum. The DHE intensity was similar in WT
and hq mice both genotypes for all ages studied and PB treatment. The DHE intensity
increased at 10 months of age within hq mice (p=0.009), however it was still not different
from WT mice. D) The ROS profile in lobule IX of the cerebellum. The DHE intensity
was similar in WT and hq mice for all ages studied and PB treatment. E) The ROS
profile in lobule X of the cerebellum. The DHE intensity was similar in WT and hq mice
for all ages studied and PB treatment. Error bars represent ± S.E.M.
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3.5. Mutation frequencies were similar in WT and hq mice but a ROS mutation
signature was more frequent in young hq mice
In total, 12.5 million plaque forming units (pfu’s) were assayed, 414 mutants were
collected and 273 independent cII mutations were identified (Table 3.1). The average
packaging efficiency was 130,000 pfu’s with a minimum of three and a maximum of six
packaging reactions per mouse. A linear regression showed that mutation frequency in
hq mice was not correlated with body mass. Spontaneous mutant and mutation frequency
showed no significant differences with mouse genotype or age. Mutation patterns were
similar between mouse genotypes and ages (Table 3.2). The majority of mutations were
G:C to A:T transitions at CpG dinucleotides followed by small deletions less than 50 base
pairs in size. Hotspots for mutation in the cII sequence were at CpG dinucleotides and
mononucleotide repeats (Figure 3.22). With one exception, single nucleotide insertions
and deletions extended or shortened mononucleotide runs. Single base pair deletions and
insertions at monobasic runs were not elevated significantly in the cerebellum of hq mice
compared to age-matched WT mice. One GC to CT tandem-base mutation was found in a
young WT mouse. This same mouse also had one mutant with seven proximal point
mutations spanning only 21 base pairs (Figure 3.22).
Four deletions, ranging in length from 10 to 21 base pairs, were found in four of
the five young hq mice. Sequences both upstream and downstream the deletion junctions
were analyzed for direct sequence repeats but none were found. These deletions were
found exclusively in the cerebellum of hq mice in this study (p=0.004) and not in our
larger database of 657 cII mutations in kidney, heart, and skin of hq and WT mice
(p=0.0001).
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Table 3.1 – Mutant and mutation frequency in the cerebellum of hq (XhqY) and wild type (XY) mice at three and
seven months of age
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Table 3.2 – Pattern of
independent mutations in
the cerebellum of hq (XhqY)
and wild type (XY) mice at
three and seven months of
age
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Figure 3.22 - Spontaneous mutations in the cII transgene harvested from the cerebellum of 3- and 7month old wild type (WT) and harlequin (hq) Big Blue® mice.

3.22 - Spontaneous mutations in the cII transgene harvested from the cerebellum of
3- and 7-month old wild type (WT) and harlequin (hq) Big Blue® mice. The
numbering convention used for the cII nucleotide positions is that reported previously
[362]. Single base substitutions are written above the base position affected. Each
independent mutation type has a superscript to designate the experimental cohort (Y = 3month-old Young wild type, W = 7-month-old middle adult Wild type, H = 3-month-old
young adulthood Harlequin, Q = 7-month-old middle adulthood harleQuin). The boxed
base pairs below the wild type sequence are nucleotides inserted and lines below the
sequence underline the nucleotides deleted. The tandem-base mutation is circled and the
seven mutations observed in a single mutant are marked with triangles.
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3.6. The transcriptomes of the cerebellum of hq mice displayed immune and
inflammatory response markers
A total of 55 genes were differentially expressed with 48 up-regulated and seven
down-regulated in the cerebellum of 3-month-old hq mice compared to WT mice with
fold changes greater than 1.5 (p<0.05, Table 3.3). Significantly altered pathways
included the classical complement system, crosstalk between dendritic cells and natural
killer cells, the neuroprotective role of thimet oligopeptidase-1 (THOP1) in AD, and
communication between innate and adaptive immune cells (Table 3.4).

3.6.1 Phenobarbital treatment had a minimal effect on the transcriptomes of WT and hq
mice
Phenobarbital treatment (4 ppm) in WT mice resulted in five differentially
expressed genes. Four genes were up-regulated and one gene was down-regulated in WT
mice treated with 4 ppm of PB when compared to untreated WT mice (Table 3.5).
Phenobarbital treatment (4 ppm) in hq mice resulted in eight differentially expressed
genes when compared to untreated hq mice. Seven genes were up-regulated and one
gene was down-regulated in hq mice treated with 4 ppm of PB when compared to
untreated hq mice (Table 3.6). For WT and hq mice treated with PB, too few genes were
differentially-expressed to perform pathway analysis.
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Table 3.3 List of differentially-expressed genes in
the cerebellum of 3-month-old hq mice compared
to age-matched wild type mice

140

141

142

143

144

145

Table 3.4
Pathways affected
significantly by
differentiallyexpressed genes in
the cerebellum of
3-month-old hq
mice compared to
wild type mice
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Table 3.5 List of differentiallyexpressed genes in the
cerebellum of 3-month-old wild
type mice treated with 4 ppm
phenobarbital compared to agematched untreated wild type
mice
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Table 3.6 List of
differentially-expressed
genes in the cerebellum of 3month-old hq mice treated
with 4 ppm phenobarbital
compared to untreated hq
mice
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CHAPTER FOUR – DISCUSSION

Given that individuals with cancer and neurodegenerative diseases have elevated
DNA damage and decreased DNA repair and given that hormesis has demonstrated
efficacy as an anti-carcinogenesis strategy in a mouse model of hepatocarcinoma, I
hypothesized that chronic low doses of PB treatment would delay cerebellar
neurodegeneration. The hq mouse had no detectable change in nocturnal behaviour
compared to WT mice and this did not change with increased age. Losses of granule and
Purkinje cells were observed in hq mice, but increased ROS and ROS-associated damage
were not the initiating factors and likely a consequence of mitochondrial dysfunction.
The transcriptome analysis implicated inflammation as an early mechanism of cerebellar
degeneration in hq mice. Unfortunately chronic low doses of PB did not delay the onset
of the symptoms associated with neurodegeneration in hq mice.
My objective was to study the effect of cerebellar degeneration on 11 different
parameters of nocturnal behaviour as measured by the ActiTrack apparatus with and
without PB treatment in WT and hq mice. Given that cerebellar function is required for
coordinated movement, I hypothesized that hq mice would have decreased nocturnal
behaviours compared to WT mice. Given that phenobarbital administration increases
activity in rodents, I hypothesized that phenobarbital administration would ameliorate
age-related decreases in nocturnal behaviours in hq mice through mechanisms that would
reduce cerebellar degeneration.
My second objective was to measure different markers of cerebellar degeneration
with and without PB treatment in WT and hq mice. Given that hq mice undergo
cerebellar neurodegeneration, I hypothesized that there would be an increase in cell loss,
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apoptosis, lipofuscin accumulation, and superoxide anion levels. Given that
phenobarbital administration affects different anti-aging pathways, then hormetic
phenobarbital administration would limit cell loss, apoptosis, lipofuscin accumulation
and superoxide anion levels.
My third objective was to determine the mutant and mutation frequency and
mutation pattern in WT and hq mice. Given that hq mice had an elevated number of
single nucleotide deletions in the brain compared to WT mice using the PLAP assay, I
hypothesized that there would be an increase in the spontaneous mutant and mutation
frequency of the cII gene and a change in the mutation pattern in the cerebellum of hq
mice when compared to WT mice.
My fourth objective was to determine what genes and pathways were altered in hq
mice with and without PB treatment early in the cerebellar degenerative process. Given
that pathways of ROS, mitochondrial dysfunction, and inflammation have been detected
in neurodegenerative disorders, I hypothesized that hq mice would have altered pathways
involved in ROS, mitochondrial dysfunction, and inflammation. Given that PB
administration may affect different anti-cancer pathways, I hypothesized that
phenobarbital administration would counter act pathways involved in ROS,
mitochondrial dysfunction, and inflammation in hq mice.

4.1 Chronic low doses of PB did not delay or ameliorate cerebellar degeneration in hq
mice
Cell loss in the cerebellum of hq mice was evident at 7 months of age and
progressed further at 10 months of age. Phenobarbital administration did not delay
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granule or Purkinje cell loss. Low doses of PB did not reduce lipofuscin accumulation or
superoxide anion levels and did not reverse the inflammatory and immune response in hq
mice. The transcriptome analysis suggests that hq mice have lower expression of a
component of the GABAA receptor, -aminobutyric acid (GABA) A receptor

6,

potentially reducing the effect of PB compared to WT mice. Although low-dose PB
treatment in hq mice was not effective at delaying or limiting cell loss, there are other
treatments available for testing in hq mice. Possible hormetic and targeted treatments are
discussed herein with the new knowledge of the mechanisms of cerebellar cell loss in hq
mice.

4.1.1 The cerebella of hq disease mice display normal early development
Cytologically and histologically there were no differences in the 3-month-old
cerebellum of hq mice compared to WT mice, suggesting that the cerebellum undergoes
normal development despite the down-regulation of Aif. Aif is required for development
as complete knockout of Aif leads to embryonic lethality at day 11.5 [251] and targeted
knockout of Aif in the cerebellum and midbrain at embryonic day 8.75 leads to lethality
after birth with both granule and Purkinje cells having aberrant cell cycles [373].
Another targeted knockout of Aif further on in development leads to normal granule and
Purkinje cell development at postnatal day 1 but lethality occurs between postnatal days 5
and 8 [373]. The two targeted knockout experiments suggest that Aif is required for
neurogenesis but the embryos are still able to develop normally for a short period of time
[373]. Thus, despite the 80% down-regulation of Aif in hq mice [232], there is enough
Aif for the cerebellum to develop normally.
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4.1.2 Unlike WT mice, hq mice show early cerebellar degeneration
With all of the biomarkers that were used to evaluate neurodegeneration in hq
mice, it appeared that in WT mice, the biomarkers did not change across the three age
cohorts tested. The number of nuclei in the granule and Purkinje cell layers did not
change with increasing age in WT mice. Previous research found that granule cell
number is constant in mice ranging from 10 to 31 months of age [124, 374].
Furthermore, granule cell numbers do not vary in the different lobules or change mediolaterally [375]. Decreased numbers of Purkinje cells are found in mice at 18, 28, or 31
months of age [124, 198, 374], which is much older than the cohorts of WT mice in the
experiment herein. Out of the 35 degeneration markers examined, the only marker that
did change with age was lipofuscin autofluorescence in lobule VIa. Since most of the
neurodegenerative markers that were used did not change with increasing age, the mixed
CBA/CaJ and C57BL/6 background is a suitable control for studying early
neurodegeneration in hq mice.
At 7 months of age, Fluoro-Jade B positive degenerating neurons were elevated
in the cerebellum of hq mice (Figure 3.19). Very few granule cells were positive for
apoptosis, but rather it was the white matter layer containing axons, cell bodies, and
neurites in the deep cerebellar nuclei where motor outputs leave the cerebellum toward
the thalamus that were degenerating at 7 months of age. Cerebellar cell loss was evident
affecting both granule and Purkinje cells. Cell loss of the granule layer was confined to
lobules IX and X, and at 10 months of age, all lobules studied had fewer granule cells
(Figure 3.14 and Figure 3.17). Additionally at 7 months of age, Purkinje cell numbers
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were reduced in all lobules assayed but lobule X (Figure 3.18). The regional patterning of
granule cell loss observed herein was similar to previous findings [232, 376] suggesting
that the down-regulation of Aif leads to an initial regional and temporal pattern of neuron
loss followed by widespread degeneration in all lobules.
Regional patterning of cell loss is not unique to the granule cell layer but was also
detected in the Purkinje cell layer in hq mice. The pattern of Purkinje cell loss in the
anterior cerebellum herein is different to a previous finding where Purkinje cell loss in 7month-old hq mice is worse in the posterior lobules in the cerebellum [232] although the
exact number of Purkinje cells are not quantified. In a different study with 8-month-old
hq mice, Purkinje cell loss is seen in the hemisphere region of the anterior cerebellum
lobules (I-V) and in the central and posterior cerebellar lobules VI-VIII [376]. In 11month-old hq mice, widespread Purkinje cell loss is extended into the vermis cerebellum
[376]. By 14 months of age, most Purkinje cells are lost, with surviving Purkinje cells
located mostly in lobule X [376]. In hq mice, Purkinje cells resistant to degeneration
express heat shock protein 25 [376]. Heat shock protein 25 is expressed in a small
number of Purkinje cells in lobule VI and VII and is expressed constitutively in lobule X
[377]. Even though heat shock protein 25 is also expressed in lobules VI and VII,
Purkinje cells in these regions are not protected from degeneration as demonstrated
herein and previous reports [376], so something in addition to heat shock protein 25 is
protective in Purkinje cells in lobule X. The cerebellum has an intricate pattern of gene
expression that is not yet fully understood. As there is a spatial and temporal pattern to
cerebellar degeneration in hq mice, knowing whether Aif or other genes are expressed in
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the different lobules at different time points would help shed light on what genes are
contributing to the spatial resistance of degeneration in granule or Purkinje cells.

4.1.3 The cerebella of hq mice do not show features of premature aging and are different
from other models of cerebellar degeneration
The anterior-posterior patterning of granule and Purkinje cell loss is not restricted
to hq mice but has also been seen in other mouse models of cerebellar degeneration.
Leaner mutant mice display massive granule cell loss in the anterior lobules of the
cerebellum [208]. Lurcher mutant mice, similar to hq mice, lose Purkinje cells in all
lobules, however, Purkinje cells in lobule X of lurcher mice that are positive for heat
shock protein 25 are more resistant to cell death [378]. In weaver mutant mice, Purkinje
cell loss occurs in all lobules but is the worst in the central lobules (VI-VII) followed by
the anterior lobules (I-V) [379]. Together, these examples demonstrate the asymmetric
molecular organization of the cerebellum, and further analysis needs to be performed to
determine whether there are temporal and spatial differences in Aif levels in the lobules of
the cerebellum resulting in the pattern of granule and Purkinje cell loss or whether the upregulation of other stress response genes, like heat shock factors in Purkinje cells are also
responsible for granule cell survival.

4.1.4 The hq mouse is a model of mitochondrial dysfunction instead of increased
oxidative stress
The hq mouse most resembles a model of mitochondrial dysfunction. Two cases
of mutated AIF have been documented in humans [254]. A trinucleotide deletion was
detected in the AIF gene at position 601-603 in exon 5, leading to the deletion of an
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arginine residue in two related individuals [254]. Both individuals had muscle weakness
and atrophy and magnetic resonance imaging of the brain revealed abnormal signals in
the neostriatum. Fibroblast cells show a reduction in the activity of complex III and IV
of the electron transport chain. Mitochondria are necessary for producing cellular energy
for the cell in the form of ATP, and defects in the components of electron transport chain
can lead to a multitude of disorders. Mitochondrial dysfunction can affect the retina
[252], brain [252, 380, 381], heart [380], skeletal muscle [252, 381], skin [382], and hair
[382]. Mitochondrial dysfunction has a frequency of 1 in 7,600 births with complex I
dysfunction being the most common [383]. Unfortunately there are no cures for
mitochondrial dysfunction. Although hq mice have been studied in different contexts
relating to neurodegeneration, the hq mouse would make a useful tool in studying the
multisystem disorder that occurs with mitochondrial dysfunction as well as testing
possible treatments.

4.2. Cerebellar ataxia did not affect nocturnal cage behaviour in hq mice
To examine the hypothesis that hq mice will have decreased nocturnal behaviours
compared to WT mice, 3-, 7-, and 10-month-old WT and hq mice were placed
individually into the ActiTrack home cage and 11 nocturnal behaviours were monitored.

4.2.1 Nocturnal cage behaviour in WT mice is unchanged with age
The observation that WT behaviour did not change with age was not unexpected.
Since the mean lifespan of CBA mice is 25 months of age and the lifespan of C57BL/6J
mice is 25-28 months of age [384], 7- or 10-month-old mice are still considered to be in
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middle adulthood and expected to have minimal behavioural changes. In fact, a recent
behavioural study in adult and aged C57BL/6 mice shows that 7-month-old and 29month-old WT mice have similar locomotor activity levels [385]. However, it is
important to keep in mind that there are strain-specific behavioural aging patterns. For
example, locomotor activity is elevated in C57BL/6 when compared to BALB/C and
DBA/2 mice [386]. Furthermore, C57BL/6 locomotor activity levels do not change
between 5 and 27 months of age whereas locomotor activity at the same ages decreases in
BALB/C mice and locomotor activity levels remain low and do not change in DBA/2
mice [386]. The mixed CBA/CaJ and C57BL/6J background was suitable as a baseline
comparison for early cerebellar degeneration.

4.2.2 hq mice have unaltered nocturnal cage behaviour compared to WT mice
Contrary to the central hypothesis, hq mice did not show evidence of decreased
nocturnal behaviours compared to WT mice and this did not change with age, which was
unexpected. Although the cerebellum plays an important role in the coordination of
movement, multiple regions of the brain are required for locomotion including the motor
cortex, thalamus, basal ganglia, brain stem, and spinal cord. The hq mice have some
apoptotic neurons in the motor cortex, thalamus, and basal ganglia at 4 months, but
neuron loss is not progressive and is limited [234]. Since the parameters of nocturnal
behaviour were similar in WT and hq mice this suggests that these other regions of the
brain involved in locomotion are resistant to neuron loss as a result of Aif deficiency.
The cerebellum is the primary site of neurodegenerative disease in hq mice and there is
limited impact on mouse nocturnal locomotor behaviour up to 10 months of age.
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4.2.3 Other models of cerebellar degeneration have behavioural changes
Other mouse models of cerebellar degeneration have either increased or decreased
activity levels when compared to control mice [227, 331-335]. Hyperactivity is seen in
both lurcher [227, 331] and reeler [332] mutant mice. Most granule cells and nearly all
Purkinje cells degenerate in lurcher mice [211]. Since Purkinje cells are inhibitory and
the only output of the cerebellar cortex, a decrease in Purkinje cells leads to a decrease in
cerebellar inhibition and can lead to an increase in excitatory messages to the motor
cortex and subsequent hyperactivity [387]. Increased cerebellar disinhibition is not likely
in reeler mice as Purkinje cell degeneration is mild with a 50% loss of Purkinje cells
[222]. Since the ratio of Purkinje cells to deep cerebellar nuclei is 10:1 in mice [210],
severe Purkinje cell degeneration is needed for a 1:1 ratio or less of Purkinje cells to deep
cerebellar nuclei and cerebellar disinhibition [226]. The hyperactivity seen in reeler mice
could be due to increased glutamate dehydrogenase activity in the forebrain [388],
possibly due to elevated glutamate, an excitatory neurotransmitter involved in locomotor
activity [389]. Weaver mutant mice, in addition to cerebellar degeneration also have
degeneration in the basal ganglia, specifically of the dopaminergic neurons in substantia
nigra pars compacta [390] that can lead to hypoactivity. On the other hand both
staggerer and leaner mutant mice have degeneration in the inferior olive [391], which
can also lead to hypoactivity [392]. These mouse models of cerebellar degeneration all
show alterations to regions of the brain other than the cerebellum and combined this leads
to altered nocturnal cage behaviour, unlike hq mice.
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4.2.4 Qualitative changes in behaviour are not tracked with an actimeter
The ActiTrack actimeter is able to quantify behaviours in mice involved in
simple movements like locomotion, stereotypes, and rearing. However, mouse behaviour
is complex and mice with neurodegeneration can have behavioural changes that may not
affect parameters of activity. A decrease in stride length and duration is detected in a
mouse model of PD [145] and an increase in stride duration and a decrease in
coordination are detected in a mouse model of ALS [147, 393]. Although behaviour did
not change with age, the location of the most severe degeneration of granule cells
occurred in lobules IX and X in hq mice, which is the location of afferent and efferent
connections with the vestibular nuclei [394-396]. Ablation of lobules IX and X in cats
leads to an unsteady gate [397], and lesions in lobules VIII-X in rats enhances tremors
induced by harmaline, a reversible inhibitor of monoamine oxidase [398]. It has been
well documented that hq mice have ataxia characterized by an unsteady gait and lateral
tremors [232, 268], but it appears that the ataxia doesn’t alter nocturnal behaviours that
were measured in hq mice. One caveat of the ActiTrack system is that it is able to
measure quantitative parameters of activity but not able to assess the quality of
movement. To better study the behaviour of hq mice with progressive
neurodegeneration, studies using rotarod, gait analysis, and video surveillance in
conjunction with nocturnal behaviour would better indicate the quality of motor
coordination and behaviour with neurodegeneration.
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4.3 Phenobarbital was delivered in a hormetic dose producing expected behavioural
effects in WT mice
4.3.1 Low-dose PB had a stimulatory effect on nocturnal behaviour in WT mice
Phenobarbital administration increases activity in rodents [299, 300], and indeed
that is the case in the WT mice herein. All the parameters that were measured showed a
significant shift towards increased nocturnal activity with the exception of the duration of
rearing events, which was not altered with PB treatment. Phenobarbital treatment of WT
mice could be described as having a biphasic or hormetic effect on behaviour. High-dose
PB treatment in mice causes inhibition of the central nervous system by binding GABAA
receptors leading to an increase in chloride ion conductivity and subsequent
hyperpolarization [296]. Low-dose PB treatment in WT mice had an overall stimulatory
affect. This excitatory action of PB has been documented before in humans and in
animals [300, 399-401]. Evidence suggests that the excitatory mechanism of PB occurs
through elevated levels of dopamine. Rats treated with PB show a two- to five-fold
increase in dopamine levels in the caudate nucleus, cortex, midbrain, and the cerebellum
and this occurs during the dark phase when rats are at their most active [402]. Another
study was able to show that the dopamine receptor blocker, haloperidol, inhibits the PB
stimulant effect on locomotor activity in mice [300]. In addition, –methyl-p-tyrosine
(AMPT), a tyrosine hydroxylase inhibitor, suppresses locomotor activity in mice treated
with PB [300]. Tyrosine hydroxylase is required for the conversion of the amino acid Ltyrosine to dihydroxyphenylalanine (DOPA) [403], a dopamine precursor, and suggests
that newly synthesized dopamine is involved in the increased locomotor activity of WT
mice treated with PB. The exact mechanism of how PB causes an increase in dopamine
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levels has not yet been elucidated but low concentrations of PB increases calcium
conductance in Aplysia [404], and calcium is able to increase tyrosine hydroxylase
activity and dopamine production [405]. Even though PB administration resulted in
increased nocturnal behaviour, prolonged exposure of WT mice to 4 ppm of PB resulted
in desensitization to PB at 7 months of age. This is consistent with physiological
tolerance to PB where the organism has increased resistance after repeated exposure to a
drug. Chronic exposure to PB in mice leads to an 18% down-regulation in the protein
levels of the GABAA receptor [406]. In rats, chronic exposure to PB leads to a 45%
decrease in the protein levels of GABAA receptor subunit

1 [407]. This suggests that

chronic exposure to 4 ppm of PB could lead to a down-regulation of the GABAA receptor
and should be confirmed. The observed stimulatory effect of PB on WT mice herein,
even at low doses, is consistent with an exposure to a dose of PB that is capable of
eliciting a response.

4.3.2 Low-dose PB increased body mass in WT and hq mice
A hypothesis that could explain weight gain in both WT and hq mice with PB
treatment is that PB stimulates feeding systems located in the hypothalamus. There is
evidence that GABA and GABAA receptors are involved in feeding behaviours. GABA
agonists, muscimol and flurazepam, when injected into the medial hypothalamus,
increases feeding behaviour while GABA antagonists inhibits feeding behaviour [408].
In addition, silencing of the Huntingtin-associated protein-1 gene, capable of stabilizing
GABAA receptors, reduces the level and activity of hypothalamic GABAA receptors and
leads to a decrease in food intake and body weight [409]. Since hq mice have down-
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regulated -aminobutyric acid A receptor,

6 (Gabra6) which is a GABAA receptor

subunit, this could decrease feeding behaviour and could explain why hq mice have a
smaller body mass and a lower rate of weight gain when compared to WT mice. Since
PB binds the GABAA receptor, it would also explain why both WT and hq mice gained
weight with PB treatment, however, the rate of weight gain was lower in hq mice which
would be consistent with a down-regulated GABAA receptor gene. The hq mice showed
a dose response effect with 4 ppm of PB having a faster rate of weight gain than 2 ppm in
hq mice, indicating that more PB is required to increase body mass in hq mice because of
the Gabra6 down-regulation. WT mice did not show the same dose response in weight
gain possibly because all the GABAA receptors were saturated with 2 ppm but also
because there may be less capacity for larger WT mice to increase in body mass
compared to hq mice. To test the hypothesis that the Gabra6 subunit down-regulation
leads to increased feeding behaviour, the daily mass of food consumed could be
measured to determine whether PB stimulates appetite in both WT and hq mice.

4.4 Elevated ROS levels do not appear to be a major driver or consequence of hq
cerebellar degeneration
To test the hypothesis that hq mice will have elevated levels of ROS, the mutant
and mutation frequency and pattern, lipofuscin autofluorescence, and superoxide anion
levels were determined for WT and hq mice at 3, 7, and 10 months of age. The
transcriptome was also examined for genes involved in the oxidative stress response.
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4.4.1 ROS-induced mutations in the nuclear DNA do not appear to be a predominant
feature of hq cerebellar degeneration
Unlike the previous observation of elevated frequency of mutation in the brain of
hq mice, the cII assay did not reveal significant elevation in spontaneous mutation
frequency in the cerebellum of hq mice in young and middle adulthood [410]. This
observation of a constant mutation frequency is consistent with previous observations
that mutation frequency is constant in the cerebellum over the mouse life span [242, 243].
Even in mouse mimics of premature aging, the frequency of spontaneous mutation would
not be expected to be significantly elevated in brain tissues. Elevated mutation frequency
in skin [240] but not cerebellum of hq mice may result from replication of skin
epithelium and fixation of mutations in comparison to the postmitotic granule neurons of
the cerebellum.
There was no change in mutation pattern in the cerebellum of hq mice compared
to WT mice at 3 and 7 months of age [410], consistent with previous observations of
relatively unchanged mutation pattern over the lifespan of the mouse [242, 243]. A
change in mutation pattern would be difficult to detect since 20 different base lesions are
associated with oxidative DNA damage [411], thus decreasing the sensitivity of the cII
assay to detect individual signature mutations for modest increases above the background
level of mutation. The most common mutation signature of oxidative stress, G:T
transversions [347], was not over represented in hq mice. Mutagenesis does not appear to
be a major driver or consequence of decreased Aif levels.
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4.4.2 Contrary to a previous report, mutation frequency in the cerebellum of hq mice was
not elevated
The observation that mutation frequency and pattern in hq mice were not different
from WT mice conflicted with a previous report where the mutant frequency was
elevated three-fold in the brain of hq mice [241]. The cII assay is a forward mutation
detection assay capable of detecting all types of base substitutions and small deletions
and insertions while the previously used PLAP assay detects the frequency of a −1 base
pair deletion at a monobasic run of 11 guanines [241]. The longest monobasic runs in the
cII mutation target are runs of six guanines and six adenines. These monobasic runs
enable comparison with the PLAP frameshift mutations, but these monobasic runs did not
show greater mutant frequency in single nucleotide deletions in the cerebellum of hq
mice at either age. Guanines are the most common target of oxidative damage and a run
of 11 guanines is hypermutable, consistent with a previous report of increased frequency
of mutations in longer repeats [412]. Guanine repeats have an innate stacking nature and
an increased susceptibility to adduct formation [413]. Oxidative stress in the brains of hq
mice combined with the susceptibility of guanine adducts and inherent instability of
guanine stacking could contribute to the previous in situ observation of increased
mutation frequency in brains of hq mice. One other possibility is the potential for the
PLAP assay to detect transcriptional errors in addition to mutation. Monobasic runs are
susceptible to both replication and transcription errors and transcriptional errors are
hypothesized to increase with increased oxidative stress associated with aging [414]. In
the PLAP assay, clusters of positive cells are consistent with mutation and replication of
mutant cells and the reversion mutation has been confirmed [415] but single isolated cells
with positive signal could be examined to confirm mutation status and rule out any
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contribution by transcriptional error. PLAP over representation could be due to
measuring errors in transcription, leading to the inflation in the mutant frequency
compared to that measured using the cII transgene.

4.4.3 One ROS mutation signature was observed in young hq mice
There was evidence of oxidative stress-induced mutations in the form of four
deletions between 10 and 21 base pairs in length identified in four out of five hq mice in
the 3-month-old cohort [410]. No homologous sequences were found in the deletion
junctions to implicate sequence context driven mechanisms and as such, these deletions
are representative of Class II deletions [371]. Class II deletions have been reported in
mice exposed to γ-radiation [371, 416] and dimethylnitrosamine [417] and associated
with elevated endogenous oxidative stress [418]. Thus, a ROS mutation signature was
detected but overall was not dramatically more frequent and not a major consequence of
the down-regulation of Aif.

4.4.4 Mutations in nuclear DNA are not associated with neurodegeneration in hq mice
The hq phenotype is not associated with elevated frequency and significant
alterations in the overall pattern of independent mutations in the cerebellum likely for
several reasons. Mutation frequency in nuclear DNA is not elevated because nuclear
DNA is protected with histones and is distant from the site of ROS production in the
mitochondria. A more plausible target of oxidative stress-induced mutation is
mitochondrial DNA. Approximately 2% of consumed oxygen is converted to superoxide
radicals during respiration [51] that can then go on to cause DNA strand breaks and base
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modifications in mitochondrial DNA [419]. Individuals with AD have 10-fold higher
levels of oxidized bases in the mitochondrial DNA compared to nuclear DNA [40].
Mitochondrial mutations have been detected in brains of AD [58], PD [420], and ALS
patients [421]. Thus in hq mice, mitochondrial DNA may be more susceptible to ROSinduced mutations than nuclear DNA. To test the hypothesis that the mitochondrial DNA
in hq mice is more susceptible to ROS-induced mutations, the mitochondrial random
mutation capture assay [422] could be used to measure mutations in WT and hq mice.

4.4.5 Lipofuscin levels in hq mice were not elevated compared to WT mice
Lipofuscin accumulation in the cerebellum was detected in hq mice and did
increase with age but was similar to cerebellar lipofuscin accumulation in WT mice.
Lipofuscin autofluorescence was elevated in lobules I/II and VIa that are located in the
anterior and central lobes of the cerebellum. Although only two lobules show an increase
of lipofuscin autofluorescence with age, one has to keep in mind that the Purkinje cells,
which are demonstrating lipofuscin autofluorescence, are also being lost with age, which
would impact the levels detected as Purkinje cells are no longer there. These lipofuscin
results in the cerebellum of hq mouse were different when compared to a previous study
of lipofuscin in the olfactory epithelium in hq mice, that found elevated lipofuscin
autofluorescence in 6-month-old hq mice and not in WT mice [245]. Even though the
olfactory epithelium in hq mice has increased apoptotic neurons when compared to agematched littermate controls, the olfactory epithelium is a site of neurogenesis that is
stimulated by neuronal cell death [423-425], thus explaining why the layers of the
olfactory epithelium have elevated lipofuscin and do not decrease in thickness or cell
number when compared to the retina or the cerebellum [232, 269, 376]. Had the Purkinje
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cells in hq mice survived, it is reasonable to think that lipofuscin autofluorescence would
have been elevated with age in hq mice compared to WT mice.

4.4.6 Superoxide anions were not elevated in hq compared to WT mice
Superoxide anions were elevated with age in hq mice in lobules I/II, III, and VIa,
but this was not different from WT mice. This pattern of elevated levels of superoxide
anions is opposite to the profile of granule cell loss. The lobules with the most initial
granule cell loss were lobules IX and X, but the ROS profiles in these lobules did not
change with age. Lobules that did not have detectable granule cell loss until late in
disease progression had a superoxide anion profile that increased with age. The
increased levels of superoxide anions with age are likely a reflection of mitochondrial
dysfunction combined with the granule cell density in individual lobules. Since oxidative
stress was not elevated initially in the 3-month-old hq cerebellum, elevated ROS is not
likely responsible for increased cell death in hq mice seen with apoptosis staining at 7
months of age, or lipofuscin accumulation in Purkinje cells.
This observation of no initial elevation of superoxide anion levels is similar to a
report of superoxide anion levels in the retina of hq mice [269] but is in contrast to other
reports that ROS is elevated in hq heart and skin [239, 240] as well as the retina of female
hq carrier mice [426]. The reason for this discrepancy is likely due to the lower number
of neurons in the cerebellum and retina of hq mice, since quantification of DHE intensity
depends on the density of nuclei containing ethidium. The heart and skin tissue of hq
mice shows increased ROS but they do not display any cell loss. The retina of the female
hq carrier mice does display cell loss, however, the phenotype is not as severe as in hq
mice [427], indicating that measurement of ROS levels in the cerebellum of hq mice were
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confounded by granule cell loss. In the future, it is suggested that the ROS levels be
normalized to the number of granule cells.

4.4.7 mRNA levels do not indicate a transcriptome response to elevated levels of ROS
Oxidative stress can lead to changes in the expression of many genes including
additional antioxidant enzymes like superoxide dismutase, catalase, glutathioine Stransferase, glutathione reductase, thioredoxin, peroxiredoxin, as well as genes involved
in DNA repair, and heat shock proteins. Only the ROS scavenger, Glutathione
peroxidase 3 (Gpx3), was up-regulated in hq cerebellum. Alterations at the mRNA level
for antioxidants other than Gpx3 were not detected, nor were there alterations in DNA
repair enzymes or heat shock proteins in hq mice. The limited number of genes related to
oxidative stress response in the transcriptome data suggests that oxidative stress may not
be a major initator of cerebellar cell loss in hq mice.

4.5 The role of AIF in the production or detoxification of ROS remains unknown
The results herein, show that hq mice did not have elevated levels of ROS or
lipofuscin at 3 months of age when compared to WT mice, which was contrary to the
expectation if one of AIF’s roles was to scavenge ROS. However, complex I deficiency
alone can lead to elevated oxidative stress [428], which could explain the increase in
ROS in hq mice with age as more mitochondria degenerate. However, AIF’s role in
scavenging ROS is based on its amino acid sequence similarity with prokaryotic
oxidoreductases [238] but conflicting results have been found about its ability to reduce
or produce ROS. In hq mice, AIF-deficiency leads to increased peroxide sensitivity in
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granule neurons [232] and cardiomyocytes [235], suggesting a protective effect of AIF as
an antioxidant. In vitro, AIF has NADH oxidase activity and mediates the reduction of
oxygen to superoxide radical [429]. In contrast, there are decreased levels of superoxide
anions generated in AIF-deficient tumour cell lines [250]. A different study shows no
difference in oxidative damage or ROS levels in WT and AIF-deficient mouse embryonic
stems cells [248]. In addition, neither the basal rate of ROS release or hydrogen peroxide
removal are different in WT and hq mice [430], so AIF's role in the production or
removal of ROS remains unclear.
To further evaluate the ROS production and detoxification function of AIF, the
NADH oxidoreductase activity of AIF needs to be further studied. NADH
oxidoreductases accept electrons from NADH and in the process convert NADH to
NAD+ to be used in various cellular processes [431, 432]. In a cell free system, AIF
oxidizes NADH and transfers electrons to molecular oxygen, ferricyanide, and
dichlorophenolindophenol (a redox indicator), but does not show any hydrogen
peroxidase scavenging activity [429]. However, this superoxide generation of AIF is not
detected in vivo and suggests that there are other substrates and targets of AIF that have
not yet been detected. Until we know what all of the substrates, targets, and proteins that
interact with AIF are, we won’t fully understand its function in the mitochondria. If
elevated ROS was the mechanism of cerebellar degeneration in hq mice, PB
administration may have been an effective treatment but more evidence is consistent with
mitochondrial dysfunction with AIF deficiency.
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4.6 Early hq mechanisms were elucidated from the transcriptome of the cerebellum
To examine the hypothesis that pathways involved in ROS, mitochondrial
dysfunction, and inflammation would be up-regulated in hq mice, a gene expression
experiment was performed in 3-month-old WT and hq mice.

4.6.1 The up-regulation of Melanoma antigen suggests that the proviral insertion in Aif is
transcribed
The Melanoma antigen (Mela) gene was up-regulated 14.5 fold in the cerebella of
3-month-old hq mice compared to WT mice. Mela is expressed during development at
embryonic day 14.5 in the central nervous system and the thymus [433]. Mela has a
similar nucleotide sequence to the env gene that is located at the 3’ end of the mouse
murine leukemia virus. The murine leukemia virus is the proviral insertion located in
intron one of the Aif gene [232], suggesting that the microarray is able to detect proviral
mRNA from the transcription of Aif. Whether the up-regulation of the env gene leads to
ENV production in hq mice is unknown and should be confirmed with a western blot to
determine ENV protein expression levels. Whether the proviral insertion in hq mice is
able to produce active viral components has not been studied, but ENV is not sufficient
on its own to cause infection and requires mature viral components [434]. Infection with
ENV induces spongiform neurodegeneration [435], which was not observed in hq mice
suggesting that ENV expression is not a cause of cerebellar degeneration in hq mice.

4.6.2 The complement pathway is activated in 3-month-old hq mice
As expected, 3-month-old hq mice had alterations in pathways involving the

169
immune and inflammatory response. The complement pathway was the most
significantly up-regulated pathway in the cerebellum of hq mice. The liver is the main
source of the complement proteins but in situ hybridization has identified complement
proteins expressed in the brain [436]. Complement component 1, q subcomponent (C1Q)
is the initial target and recognition protein of the complementation pathway and is
required for the clearance of pathogens and apoptotic cells [437]. C1Q has a
heterotrimeric structure composed of 18 polypeptide chains, 6 each of C1QA, CIQB and
C1QC [438]. Both C1qb and C1qc were up-regulated in the cerebellum of 3-month-old
hq mice, but C1qa is also required to form the C1Q complex. C1qa had a fold increase
of 1.3 and did not make the 1.5 fold cut off for the microarray analysis, consistent with a
limited sensitivity of the microarray technology to detect small increases in fold change
due to the dilution of gene expression by the heterogeneous cell types in the brain [439].
However, small increases in fold change still have a biological impact [440], as
evidenced by the fact that full C1Q complex is needed for the activation of the
complement pathway, and genes downstream of C1Q were up-regulated in the
cerebellum of 3-month-old hq mice, including Complement component 3a receptor 1
(C3ar1) and the basic form of Complement component 4b (C4b). In the cerebellum of 4month-old hq mice, C1qa is up-regulated as well as C1qb and C1qc [427]. With the C1Q
complex assembled, it is able to directly bind to apoptotic cells resulting in the activation
of the classical complement pathway [437] and facilitates the clearance of apoptotic cells
by microglia. The fact that genes in the complement cascade were up-regulated, in
particular the early activation products, shows that there was initiation of the
phagocytosis response to get rid of apoptotic cells as early as 3 months of age in the
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cerebellum of hq mice. Also, the limited number of degenerating neurons also supports
effective clearance of apoptotic cells. Up-regulation of the complement pathway in hq
mice compared to WT mice still needs to be validated with real time PCR or protein
expression.
Although complement activation is required in defense against pathogens and
removal of apoptotic cells, constant up-regulation is detrimental and leads to host tissue
damage. Complement activation has been implicated in normal aging [200-202, 290,
291] and the pathogenesis of several diseases including systemic lupus
erythematosus/rheumatoid arthritis [441], multiple sclerosis [442], spinal cord injury
[443], psoriasis [444], age-related macular degeneration [445], and neurodegenerative
diseases [436, 446, 447]. Complement proteins are associated with amyloid deposits in
AD [448]. A mouse knockout of C1q crossed with APP transgenic mice, shows
decreased glial cell activation without reducing amyloid deposition, suggesting a role for
complement activation in the pathology of AD [449, 450]. In early stages of AD, the
presence of the early complement components is found in plaques including C1Q, C4D
and C3D but components C5B-9 are absent [451, 452]. At later stages of AD, in addition
to C1Q, C4D, and C3D, C5B-9 are present in plaques and neurofibrillary tangles [453],
further suggesting a role for early complement activation in AD. In addition, the
prominence of early complement components is in line with a study comparing a
transgenic mouse model of AD to WT mice [454], which is similar to what was found
here in the cerebellum of 3-month-old hq mice suggesting that early complement
components play a role in neurodegeneration in hq mice.
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4.6.3 There was up-regulation of the pathway termed crosstalk between dendritic cells
and natural killer cells
There was significant up-regulation in the crosstalk pathway between dendritic
cells and natural killer cells. Dendritic cells and natural killer cells are both components
of the immune response in the circulatory system. Dendritic cells process antigens and
present antigenic material on their surface leading to activation of other immune cells.
Natural killer cells are lymphocytes, capable of killing cells that have been infected with
viruses or cells that are cancerous. Genes that were up-regulated in this pathway
included TYRO protein tyrosine kinase binding protein (Tyrobp), the major
histocompatibility complex I (MHC1) component Histocompatibility 2, K1, K region
(H2-K1), and Actin alpha 2 smooth muscle aorta (Acta2). TYROBP is an adaptor
molecule that binds to activating receptors on the natural killer cells and is required for
natural killer cell activation [455]. Since dendritic and natural killer cells are part of the
immune system in the circulatory system, it is unlikely that the cells were able to
infiltrate the cerebellum through the blood-brain barrier. Since microglial cells are the
macrophages of the central nervous system, it is possible that both Tyrobp and H2-K1
were up-regulated due to microglial activation. TYROBP is expressed in microglial cells
and up-regulation can lead to an increase in superoxide formation and can lead to
increased apoptosis [456]. H2-K1 can also be expressed in microglial cells after
engulfment of apoptotic cells [457]. The Acta2 gene codes for -actin in vascular
smooth muscle cells and is important for the contractile function in vasculature [458].
Since down-regulation of Acta2 results in a decrease in the structural integrity of
vasculature, and mutations in Acta2 can lead to familial aortic aneurisms [459], up-
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regulation of the Acta2 gene could be due to maintenance of the integrity of the bloodbrain barrier in hq mice. In hq mice, blood vessels are thicker, longer, and more
numerous compared to WT mice [234] indicating maintenance of the blood-brain barrier.
Up-regulation of Tyrobp, H2-K1, and Acta2 suggests microglial activation in the
cerebellum rather than infiltration from the circulatory system by dendritic and natural
killer cells due to a compromised blood-brain barrier in 3-month-old hq mice.

4.6.4 There is maintenance of the extracellular matrix and an active immune response
In hq mice, genes that were up-regulated in the neuroprotective role of THOP1 in
Alzheimer’s disease pathway included Serine peptidase inhibitor, clade A, member 3N
(Serpina3n) and H2-K1. THOP1 is a metalloprotease that has been associated with APP
[460] processing and the indirect degradation of the amyloid

[461] thereby preserving

the integrity of axons and dendrites and maintaining connectivity and extracellular matrix
functionality of neurons in AD. Despite the neuroprotective role of this pathway, the
differentially-expressed genes that were up-regulated have a detrimental role in the
THOP1 neuroprotective pathway. SERPINA3N is closely associated with amyloid
[462] and decreased THOP1-dependent amyloid
inhibiting amyloid

degradation by 60% [461] either by

degrading proteases or preventing proteases in the brain from

clearing APP thus contributing to amyloid deposits. In addition, SERPINA3N is detected
in astrocytes in normal human aging [462] suggesting that Serpina3n overexpression is
not limited to pathology in AD. Serpina3n co-localizes with astrocytes in the retina after
inflammatory stimulation with lipopolysaccharide [463]. The co-localization of
Serpina3n and astrocytes could be beneficial as SERPINA3N can inhibit Cathepsin G
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and Elastase, which can hydrolyze proteins in the extracellular matrix [464]. Since hq
mice don’t have amyloid

pathology, SERPINA3N would have a beneficial effect in

limiting breakdown of the extracellular matrix in the cerebellum of hq mice. THOP1 also
hydrolyzes oligopeptides ranging in size from 6-17 amino acids in length [465] including
antigenic peptides [466] thus limiting MHC I presentation [467], which could eventually
lead to suppression of the immune response. However, in the cerebellum of 3-month-old
hq mice the MHCI component was up-regulated suggesting an increased immune
response. Thus, it is possible that hq mice have down-regulated the neuroprotective role
of THOP1 in Alzheimer’s disease pathway leading to a maintenance of the extracellular
matrix and increased immune response. Validation is still needed with real time PCR or
protein expression.

4.6.5 Immune response activation is consistent with microglial activation
The final pathway up-regulated in hq mice related to immune response was
communication between innate and adaptive immune cells. The two genes that were upregulated in the communication between innate and adaptive immune cells pathway were
Chemokine (C-C motif) ligand 3 (Ccl3) and H2-K1. The innate immune system is an
immediate defense system used to protect the host from infection from pathogens through
the production of chemokines and inflammatory cytokines. The adaptive immune system
is activated by the innate immune system and provides an organism with the ability to
recognize and remember specific pathogens so that it may trigger stronger attacks each
time the same pathogen is encountered. The innate and adaptive immune systems can be
activated through microglial activation [468]. Microglial cells are the resident
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macrophages of the central nervous system and are activated by infection, injury, or
apoptotic cells [62]. CCL3 is a chemokine secreted by activated microglial cells in order
to attract additional microglial cells to the point of injury [468]. Microglial cells are
antigen presenting cells, capable of expressing MHC I and II. Histocompatibility 2-K1 is
one of the components of the MHCI antigen [469] and is presented on the surface of
microglial cells after phagocytosis of dead or foreign cells [457]. Since pathways related
to immune responses were up-regulated in the cerebella of 3-month-old hq mice without
any evidence of invading bacteria, viruses, or a compromised blood-brain barrier, a more
plausible hypothesis is that an immune response is occurring in the cerebellum through
the activation of microglial cells by damaged or apoptotic neurons. Indeed, manual
annotation of the differentially-expressed genes, revealed markers of microglial
activation and needs further validation.

4.6.6 Multiple transcripts identified by gene expression indicate microglial activation
Microglial activation is associated with the release of ROS [73], proteases [74], and
inflammatory cytokines [70]. Markers of microglial activation in hq mice included Ccl3,
which attracts microglia to the site of injury [468]. Cluster of differentiation 68 (Cd68) a
cell surface glycoprotein present on activated microglial cells [470]. Cluster of
differentiation 93 (Cd93), also known as Complement component 1 subcomponent
receptor 1 (C1QR1) that is required for the engulfment of apoptotic cells by microglia
[471]. Histocompatibility 2-K1 (H2-K1), is one of the components of MHCI [469] and is
presented on the surface of microglial cells after phagocytosis of dead or foreign cells
[457]. In addition, Lysozyme 2 (Lyz2) and Cathepsin S (Ctss) are proteases present in
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lysosomes of microglial cells. Lyz2 is required for the degradation of apoptotic cells
[472] and Ctss is required for MHC II presentation [473] and for degradation of the
extracellular matrix [474]. Microglial activation is a necessary component in the removal
of cellular debris in the brain, but constant stimulation or unregulated response of
microglial cells leads to inflammation. Microglial activation and inflammation is
prevalent in neurodegenerative disorders including AD [82], PD [82], and ALS [86]. The
up-regulation of microglial markers suggests activated microglia play a role in the early
stages of neurodegeneration of the cerebellum of 3-month-old hq mice.

4.6.7 Similar cerebellar transcriptome features exist in 3 and 4-month-old hq mice
Reproducibility of scientific results is a fundamental principle in scientific
research. This is of particular importance with microarray technology, which has been
known to show a high amount of variability in lists of differentially-expressed genes
[475]. Variability can be explained by the use of different platforms and laboratory
processing but the reproducibility herein was found in the gene list in the cerebellum of
3- and 4-month-old hq mice. Of the 55 differentially-expressed genes found in the
cerebellum of 3-month-old hq compared to WT mice, 48 were also differentially
expressed in the cerebellum of 4-month-old hq compared to WT mice (Appendix B,
Table B.1) [427]. And in both cases, the fold change was in the same direction for genes
that were differentially expressed. Genes that were not reproduced included a predicted
gene of unknown function (Gm11428), an enzyme that converts ethanol to acetaldehyde
(Adh1), a nicotine, acetylcholine, and cation ligand channel (Chrnb4), a guide RNA
involved in methylation of pre-rRNA (Snord82), a lipid kinase that is a negative regulator
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of apoptosis (Cerkl), a receptor for the neurotransmitter GABA (Gabra6), and a
mitochondrial protein involved in the assembly and/or maintenance of complex I in the
electron transport chain (Aifm1). However, down-regulation of Aifm1 was confirmed
through Taqman® assays in hq mice at 5 weeks of age, 4 months of age and 7 months of
age for both the retina and cerebellum (Edwards, unpublished)(Thwaites, unpublished)
[476]. Ctss up-regulation was confirmed with Taqman® assays in the cerebella of hq
mice at 5 weeks and 4 months of age (Thwaites, unpublished). Thus, most of the genes
in the cerebellum of 3-month-old hq mice were replicated in the cerebellum of 4-monthold hq mice.

4.6.8 Similarities and differences exist between cerebellar and retinal transcriptomes in
hq mice
Altered pathways in the cerebellum of 3-month-old hq mice included those
involved in the immune and inflammatory response. This is similar to a report of gene
expression in the retina [427] and cerebellum of 4-month-old hq mice (Appendix B,
Table B.1) [427]. At 4 months of age, both the retina and cerebellum show evidence of
altered metabolism with a shift to glycolysis [427], as a result of reduced oxidative
phosphorylation [248]. When glycolysis is inhibited in AIF-deficient embryonic stems
cells, there is increased cell death [248] suggesting an increased dependence on
glycolysis for ATP production. Similarly, altered pathways in the retina in 4-month-old
hq mice are involved in immune and inflammatory response as well as altered
metabolism with a shift to glycolysis [427].
One difference between the cerebellum and retina is that the retina appears to
have an earlier onset of degeneration compared to the cerebellum. In the retina,
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functional deficits measured by electroretinography, are observed as early as 2 months of
age in hq mice [269], apoptotic retinal cells are detected at 3 months of age [232], and
retinal structural deficits are first seen in the ganglion cell layer and outer nuclear layer at
4 months of age [269]. In the cerebellum, apoptotic cells are first seen at 4 months of age
in the hq mice leading to a decrease in rotarod performance, a measure of motor coordination, at 6 months of age [233] and structural deficits in the granule and Purkinje
cell layer of the cerebellum at 7 months of age [232]. Although, it should be noted that
the retina has had a detailed monthly characterization of the degeneration in different
layers, whereas, the cerebellum has been studied at a fewer number of time points, so
comparisons between the two tissues are difficult. One difference in the disease
mechanism between the retina and cerebellum is that the retina of hq mice shows
evidence of extracellular matrix remodeling. Altered pathways identified in the retina of
4-month-old hq mice are related to extracellular matrix receptor interaction, focal
adhesions involved with the regulation of the extracellular matrix, and cytoskeletal
elements [427]. In addition, hematoxylin and eosin staining shows nuclear displacement
in the retina [269, 426], confirming remodeling of extracellular matrix. In contrast, the
cerebellum did not show altered gene expression in pathways involved in extracellular
matrix remodeling or nuclear displacement of the granule or Purkinje cells.

4.6.9 Transcriptome changes with degeneration of hq olfactory epithelium implicated
different underlying mechanisms
The reports on gene expression in the retina and cerebellum differ when compared
to the olfactory epithelium in hq mice. None of the differentially expressed genes in the
cerebellum of 3- and 4-month-old hq mice were detected in the olfactory epithelium in 6-
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month-old hq mice [245]. In the olfactory epithelium, altered genes are classified into
cell signaling/apoptosis, oxidative stress/aging, cytoskeleton/extracellular matrix,
transport, and neurogenesis pathways [245]. Several reasons could explain this
discrepancy, the first being that the tissues although they are neural, could have different
degeneration timelines. This has been demonstrated for the retina and the cerebellum in
hq mice. Retinal degeneration is detected as early as 2 or 3 months of age and cerebellar
degeneration occurs at 4 months of age [232, 234, 269], but since there is only one study
in the olfactory epithelium in hq mice [245], a neurodegenerative timeline has not been
established for the olfactory epithelium. In addition, different ages of hq mice have been
studied thus far, and at 6 months of age, disease progression in the olfactory epithelium is
well underway, whereas 3 months of age is considered early in the disease onset [232,
234]. Also, the olfactory epithelium is directly exposed to the external environment
unlike the cerebellum, and exposure to environmental agents could alter gene expression.
Thus, the underlying mechanisms of neurodegeneration in the olfactory epithelium need
to be characterized further with an increased number of time points to better compare the
differences in the neurodegeneration timeline.

4.7 Chronic low-dose PB treatment produced few alterations in the transcriptome of
the cerebellum
4.7.1 The effect of PB on the transcriptome in the cerebellum was limited in WT and hq
mice
Phenobarbital treatment had little effect on the transcriptome in WT and hq mice
and may not be acting through the induction of gene expression. Administration of 10
mg/kg/day of PB for 28 days leads to very little change in the gene expression in the
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liver, as two genes were up-regulated and three genes were down-regulated more than 1.5
fold [477]. Even at a higher dose, 100 mg/kg/day, only seven genes are up-regulated and
one gene is down-regulated more than 1.5 fold. The two genes that are up-regulated with
10 mg/kg/day are both cytochrome P450 enzymes. Enzyme activity assays, however,
show increased activity for four different cytochrome P450 enzymes even though
alteration in the gene expression is not significant [477], suggesting that PB may work
through the induction of enzyme activity rather than a change in gene expression in the
brain.

4.7.2 Down-regulation of the GABAA receptor may impede the effectiveness of PB
The gene expression assay showed that hq mice have a down-regulated Gabra6
gene, potentially leading to down-regulation of functional GABAA receptors. A downregulation in functional GABAA receptors could explain why PB treatment had little
effect on the behavior of hq mice. Additionally, hq mice require increased levels of
ketamine anesthetic for sedation during retinal function testing because hq mice are
coming out of sedation earlier than expected. Current literature suggests that ketamine is
able to act upon GABAA receptors, in particular the alpha6beta2delta receptor subtype,
as well as the N-methyl-D-aspartic acid receptors to produce the anesthetic effect [478].
Both the lack of activity of hq mice with PB administration and the increased ketamine
doses required for sedation in hq mice are consistent with the hypothesis that hq mice
have decreased Gabra6 levels. To test the hypothesis that hq mice have a decreased
amount of the GABRA6 subunit, a western blot could be performed to determine levels
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of the subunit in WT and hq mice. Decreased Gabra6 levels potentially make PB an
unsuitable hormetic agent in hq mice.

4.8 The hq disease mechanisms and phenotype are consistent with mitochondrial
dysfunction
While PB treatment did not reveal any benefit in WT or hq mice, the data are
consistent with disease mechanisms associated with mitochondrial function. In cell
culture, AIF-deficient cells have compromised oxidative function and rely on ATP
generated from glycolysis [248] suggesting that decreased AIF leads to mitochondrial
dysfunction. Degenerating mitochondria are seen as early as 2 months of age in hq
cerebellum and the rate of degenerating mitochondria increases progressively starting at
41% at 2 months of age to 81% at 6 months of age in cerebellar granular cells [234]. At
4 months of age, transcriptome analysis in the retina and cerebellum reveals altered
metabolism with various genes related to glycolysis [426]. Also, mitochondrial complex
I deficiencies are tissue specific. In humans, tissues that can be adversely affected by
mitochondrial complex I deficiencies include the retina [252], brain [252, 380, 381], heart
[380], skeletal muscle [252, 381], skin [382], and hair [382]. A mouse model of complex
I deficiency, displays a decreased growth rate, ataxia, blindness, and encephalomyopathy
[479]. In humans and mice, the symptoms of the mitochondrial complex I deficiencies
are similar to symptoms in hq mice. Since mitochondrial dysfunction leads to elevated
ROS production [480], this would explain increased lipofuscin and ROS with age in hq
mice. Since we know that there is a lobule specific pattern of neuron loss, one caveat of
the study regarding mitochondrial dysfunction in hq mice [234], was that it did not
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specify the mitochondrial dysfunction on a per lobule basis in hq mice to see whether
lobules IX and X had more dysfunctional mitochondria relative to the other lobules.
Elevated ROS are likely a consequence of mitochondrial dysfunction and do not appear
to be associated with early cerebellar degeneration in hq mice. Thus, the cause of
degeneration is likely mitochondrial dysfunction leading to a decrease in ATP production
and eventually cell death. In order to prevent cerebellar degeneration in hq mice,
mitochondrial dysfunction would have to be addressed either through increasing the
amount of complex I, or by increasing the efficiency of the electron transport chain.
Phenobarbital treatment did not address the mitochondrial dysfunction aspect of the hq
cerebellar degeneration thus, the targets of PB that made it successful in preventing
cancer, did not make it successful in preventing or delaying cerebellar degeneration in hq
mice. Thus, PB was not a suitable choice as a hormetic agent in hq mice.

4.9 Other hormetic therapies can be considered for cerebellar degeneration in hq mice
4.9.1 Caloric restriction may reverse inflammation
Although, hq mice treated with low doses of PB did not show a hormetic
response, this does not mean that other hormetic agents would also prove to be
ineffective in hq mice. Caloric restriction has been extensively studied for its ability to
increase lifespan in species of yeast [481] to mammals [289]. Also, caloric restriction
decreases lipofuscin accumulation in the different regions of the brain [482], decreases
ROS production [483], decreases damaged lipids and proteins [291, 484], and increases
mitochondrial membrane potential in yeast [485]. Mitochondrial energy production
relies on the membrane potential so an increase in mitochondrial membrane potential
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would lead to an increase in ATP production, however, ATP levels are not altered under
caloric restriction and non-caloric restriction conditions [486]. Gene expression analysis
in the brain of mice shows that caloric restriction has varied effects depending on the
region of the brain studied, but gene expression in regions of the central nervous system
are still more similar to each other than they are to other organs [290]. Aging leads to
increased expression of complement components as well as antigens (Cd48, Cd52, Cd53)
in multiple brain regions, including the cerebellum, and caloric restriction is able to
oppose the effects of aging in genes associated with immunity, defense, and inflammation
[200, 202, 290, 291]. Generally, caloric restriction can counter some age-associated
changes in gene expression, immune response, and inflammation, but is not able to
reverse all age-associated changes in gene expression [290]. Thus far, caloric restriction
appears to be the most promising anti-aging strategy available. It would be interesting to
study caloric restriction in the context of neurodegeneration to see whether the beneficial
effects of reduced caloric intake can lead to decreased neurodegeneration in hq mice.
Although, caloric restriction would be a difficult strategy to employ in the human
population, understanding of the molecular mechanisms leading to increased longevity is
needed. Perhaps in the future there will be developments of drug compounds that can
mimic the beneficial effects of caloric restriction without having to decrease caloric
intake. Caloric restriction could reduce the inflammatory and immune responses in the
cerebellum of hq mice.
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4.9.2 Physical exercise may increase the electron transport chain efficiency
Exercise has shown promise in slowing the decline of neurodegeneration in
mouse models of AD, PD, and mitochondrial DNA mutator mice [293, 294, 487].
Exercise is able to ameliorate the decline in mitochondrial DNA and components of the
electron transport chain in 3xTg-AD mice [129], and protects against mitochondrial
dysfunction in a PD mouse model by increasing mitochondrial respiration, and ATP
production [294]. In the mitochondrial DNA mutator mouse, exercise is able to increase
mitochondrial copy number while reducing the frequency of mutations in the
mitochondrial DNA, increasing the amount of mitochondrial electron transport chain
subunits, and increasing mitochondrial activity [487]. Although exercise is beneficial in
these mouse models, it might not be as beneficial in hq mice because exercise decreases
adipose tissue in the 3xTg-AD mice [129], and hq mice have very little adipose tissue.
Nonetheless, exercise shows promise in ameliorating the decline in mitochondrial
function in neurodegenerative diseases, and could be a possible strategy to use in hq
mice.

4.10 Riboflavin administration is a targeted therapy that may increase the electron
transport chain efficiency
Since hq mice have decreased Aif expression leading to decreased complex I
assembly [430], activity, and ATP production [248], another possible treatment would be
to increase the amount of assembled complex I in the mitochondria to restore complex I
activity and ATP production. Riboflavin is a precursor for flavin adenine dinucleotide
and flavin mononucleotide that is required for redox enzymes in energy metabolism.
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Oral treatment with riboflavin in doses ranging from 9 mg in children to 100 mg in
adults, increases complex I activity in the muscle of three out of the five individuals
tested, as well as decreasing lactate levels in both the serum and cerebrospinal fluid
[488]. The sample size of the previous study is very small but the results in the literature
are fairly consistent. Administration of riboflavin, sometimes in conjunction with other
components, is able to successfully treat different patients [254, 489-492]. Riboflavin
supplementation in C. elegans is able to increase the activity and the amount of fully
assembled complex I but the exact mechanism is not known [493]. Riboflavin has very
low toxicity as demonstrated by administering riboflavin orally at 10 g/kg of body weight
in rats with no toxic effects [494]. Riboflavin is also capable of crossing the blood-brain
barrier with the human riboflavin transporter hRFT3, which is highly expressed in the
brain [495]. In humans with manifestation of complex I deficiency in the muscles, rather
than manifestation in both muscles and central nervous system, fare better with riboflavin
treatment [253, 488, 496], suggesting that riboflavin may not be as effective in hq mice as
the main effects of complex I deficiency are seen in the cerebellum and retina but defects
can also be seen in the cardiac muscle of hq mice in conjunction with added stressors
[235]. One reason for this could be that riboflavin levels in the brain remain fairly
constant despite diets rich or deficient in riboflavin [497]. Despite the drawback, it
would still be of interest to test riboflavin administration as a potential treatment in
cerebellar degeneration in hq mice.

185
4.11 Caveats
The transcriptome data should be confirmed at the protein level. A change in the
mRNA expression of a gene may not reflect a change in the protein expression [498], as
there are mechanisms of post-transcriptional control including microRNAs [499], and
RNA binding proteins [107]. There are also mechanisms of post-translational control
that can regulate protein activity including phosphorylation, acetylation, glycosylation,
ubiquitination, and cleavage. Indeed, if there are changes in the protein expression, this
may still not result in an up- or down-regulation in a pathway as many genes are involved
and a change in the expression of one gene may not lead to a change in the overall
pathway. The next step would be to confirm the gene expression data at the protein level
with western blotting.
Another caveat regarding the Fluoro-Jade B stain is that the identity of the
compound that Fluoro-Jade B binds to in degenerating neurons in unknown. FluoroJade B is a poly-anionic fluorescein and thus is thought to bind to molecules with
multiple positive charge groups, but the exact protein has not been determined [500].
Because the mechanism of action is unknown it is still uncertain at what time point
during the degeneration process this molecule with affinity to Fluoro-Jade B is
expressed. The use of Fluoro-Jade B could lead to increased false negatives, neurons
that were degenerating but not stained with Fluoro-Jade B. For an example, a previous
study compared the use of terminal deoxynucleotide transferase-mediated, deoxyuridine
triphosphate nick-end labeling (TUNEL) and Fluoro-Jade B in the leaner mutant mouse
[501]. A total of 796 granule cells were evaluated using TUNEL, Fluoro-Jade B and
double staining for both TUNEL and Fluoro-Jade B. Only staining with TUNEL
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yielded 29.5% positive granule cells while only staining with Fluoro-Jade B yielded
17.5% positive granule cells. Double staining for both TUNEL and Fluoro-Jade B
yielded 53% positive granule cells. To improve the accuracy of detecting degenerating
neurons, staining with both TUNEL and Fluoro-Jade B should be incorporated in future
studies.

4.12 Summary and Conclusions
This was the first characterization of nocturnal behaviour in hq mice and it was
determined that nocturnal activity is not affected by cerebellar degeneration. No new
early behavioural markers of cerebellar degeneration were identified. This was the first
quantitative characterization of cerebellar degeneration in hq mice with normal aging
while previous studies of hq mice focused on qualitative aspects of granule and Purkinje
cell loss [232, 376]. Both granule and Purkinje cell numbers decreased in hq mice and
cell loss had an anterior-posterior patterning. This pattern of cell loss in the hq
cerebellum may provide insight into early mechanisms of degeneration and provide
benchmarks for assessing the efficacies of potential treatments. This was the first
characterization of mutations in the cerebellum of hq mice using the Big Blue cII
mutation detection assay which determined that nuclear mutations did not play a large
role in cerebellar degeneration. A detailed characterization of the transcriptome was
achieved in the cerebellum of 3-month-old hq mice. The transcriptome data were
consistent with inflammation and microglial activation as early mechanisms in cerebellar
degeneration in hq mice. Preventing the inflammatory response early in hq mice may
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help to stem cerebellar degeneration. A down-regulation of Gabra6 may explain the lack
of response by hq mice to low doses of PB.
Multiple lines of data do not show association of ROS with cerebellar
degeneration in hq mice. Superoxide anion levels and ROS-induced damage such as
lipofuscin and mutations were not the major contributing factors to cerebellar
degeneration as was previously suggested. Lipofuscin accumulation, mutations, and
ROS were not elevated initially in the cerebellum of hq mice early in disease progression,
suggesting that a decrease in energy production due to mitochondrial dysfunction was the
major contributing factor to cell death. Mitochondrial dysfunction also led to an
elevation in the mRNA of genes related to the inflammatory response in the cerebellum
of hq mice. Thus, mitochondrial dysfunction and inflammation would be potential
targets for therapies in preventing cerebellar degeneration in hq mice.
New treatment targets indicated for use in preventing cerebellar degeneration in
hq mice were identified. Although, low-dose administration of PB was unsuccessful in
treating cerebellar degeneration, this does not mean that hormesis cannot be effective in
hq mice. Caloric restriction could be used to reverse inflammation and exercise can
increase complex I activity. In addition, one other targeted treatment was documented.
Riboflavin administration has shown efficacy in increasing complex I activity of the
electron transport chain and has been an effective treatment in humans with
mitochondrial dysfunction. Future studies assessing the effectiveness of riboflavin to
prevent or delay cerebellar degeneration in hq mice should be done.
The function AIF and its effect on ROS are still unexplained. Even though
evidence of ROS-induced damage was not overwhelming in the data presented herein,
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superoxide anion levels and lipofuscin increased with age, and a ROS mutation signature
was identified. Previous research in hq mice has reported evidence of ROS-induced
damage [232, 241, 245, 280], as well as sensitivity of neurons and cardiomyocytes to
exogenous ROS [232, 235, 502], suggesting an antioxidant role for AIF. However, the
rate of ROS production or detoxification was similar in WT and hq mice [430] and yet,
AIF accepts electrons from NADH and transfers them to molecular oxygen to produce
superoxide anions in vitro [429]. If AIF has the ability to accept and transfer electrons, it
is possible that AIF is involved in the transfer of electrons from NADH or an unidentified
associated protein to another associated protein for detoxification. In the absence or
down-regulation of AIF, there would not be an increase in ROS but rather a
mismanagement of ROS, which would lead to increased oxidative damage but not
increased ROS production.
This research has furthered our knowledge of the mechanisms of cerebellar
degeneration in hq mice. Phenobarbital may be a suitable treatment in preventing
hepatocarcinogenesis, but the data do not support its efficacy in preventing
neurodegeneration in hq mice. Alternatively, potential hormetic and targeted therapies
were suggested in treating mitochondrial dysfunction and inflammation in hq mice. The
key to unlocking the mystery of AIF remains in discovering the function of AIF in the
context of ROS and its involvement in the assembly and/or maintenance of complex I.
Further understanding of the role of AIF in these two capacities could advance our
knowledge of the complex I assembly and the necessary factors required for proper
function. Since mitochondrial dysfunction is a common feature of neurodegenerative
diseases, insight into the factors required for proper mitochondrial function would be
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beneficial in testing treatments for mitochondrial dysfunction or neurodegenerative
diseases.
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Appendix B – Supplementary Figures and Tables
This appendix contains a supplementary figures and tables used to aid in understanding
of research presented within this study.
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Figure B.1 – Identification of apoptotic neurons in the mouse cerebellum of wild
type (WT) and harlequin (hq) mice. A) An image of the cerebellum of a WT mouse
stained with Fluoro-Jade® B with no visible degenerating neurons. B) An image of the
cerebellum of a hq mouse stained with Fluoro-Jade® B, with the white arrow indicating
degenerating neurons. C) The negative controls were created by injecting WT mice with
10 mg/kg of a vehicle control. D) The positive controls were created by injecting WT
mice with 10 mg/kg of paraquat. Scale bar = 100 µm.
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Figure B.2 – Identification of lipofuscin autofluorescence indicative of damaged
lipids and proteins in cerebellum of wild type (WT) and harlequin (hq) mice. A) An
image of the yellow and green autofluorescence in the apex of lobule I/II of the
cerebellum of a WT mouse. The white arrows are indicating lipofuscin autofluorescence.
B) An image of the yellow autofluorescence of the apex of lobule I/II of the cerebellum
of a WT mouse after setting the 140 threshold to remove the green autofluorescence. The
white arrows are indicating lipofuscin autofluorescence. C) A hematoxylin and eosin
image of the apex of lobule I/II of the cerebellum of a WT mouse showing the location of
the lipofuscin in the Purkinje cell layer. Six yellow autofluorescence measurements were
made at the apex of lobules I/II, III, VIa, IX, and X for two different cerebellar sections.
The yellow autofluorescence measurements for the two separate sections were averaged
together. Yellow autofluorescence measurements were taken in three different mice per
experimental group. Scale bars = 100 µm
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Figure B.3 – Identification of reactive oxygen species (ROS) in the mouse
cerebellum of wild type (WT) and harlequin (hq) mice. A) A hematoxylin and eosin
image of lobule I/II of the cerebellum of a 3-month-old WT mouse. B) A fluorescent
image of lobule I/II of the cerebellum of a 3-month-old WT mouse stained with
dihydroethidium (DHE). C) A fluorescent image of lobule I/II of the cerebellum of a 3month-old hq mouse stained with DHE. Three DHE fluorescence measurements were
made at the apex of lobules I/II, III, VIa, IX, and X for two different cerebellar sections.
The DHE fluorescence measurements for the two separate sections were averaged
together. DHE fluorescence measurements were taken in three different mice per
experimental group. D) An image of a positive control of lobule I/II of the cerebellum of
a 3-month-old hq mouse. The positive control was created by exposing sections to 0.5 M
hydrogen peroxide for 5 min prior to DHE staining. E) An image of a negative control of
lobule I/II of the cerebellum of a 3-month-old hq mouse created by exposing sections to
20 l of 1000 U/ml superoxide dismutase solution for 10 min prior to DHE staining. F)
An image of a negative control of lobule I/II of the cerebellum of a 3-month-old hq
mouse created by staining with dimethyl sulfoxide (DMSO) in the absence of DHE
staining. Scale bars = 100 µm
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